var title_f7_23_7536="Papillitis";
var content_f7_23_7536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F67875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F67875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Papillitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Don C Bienfang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_23_7536=[""].join("\n");
var outline_f7_23_7536=null;
var title_f7_23_7537="Vaginal dryness";
var content_f7_23_7537=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Vaginal dryness (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/23/7537/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7537/contributors\" id=\"au797\">",
"       Gloria Bachmann, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7537/contributors\" id=\"au5618\">",
"       Richard J Santen, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/23/7537/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7537/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/23/7537/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7537/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?7/23/7537?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      VAGINAL DRYNESS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Vaginal dryness, also known as atrophic vaginitis, is a common condition in postmenopausal women. This condition is also common in women who have had both ovaries removed at the time of hysterectomy.",
"    </p>",
"    <p>",
"     Some women have uncomfortable symptoms of vaginal dryness, such as pain with sex, burning vaginal discomfort or itching, or abnormal vaginal discharge, while others have no symptoms at all.",
"    </p>",
"    <p>",
"     Fortunately, there are several effective treatments for vaginal dryness. If you think you have vaginal dryness, talk to your healthcare provider about which treatment is right for you. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=see_link\">",
"      \"Clinical manifestations and diagnosis of vaginal atrophy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      VAGINAL DRYNESS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Estrogen helps to keep the vagina moist and to maintain thickness of the vaginal lining. Vaginal dryness occurs when the ovaries produce a decreased amount of estrogen. This can occur at certain times in a woman's life, and may be permanent or temporary. Times when less estrogen is made include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       At the time of menopause.",
"      </li>",
"      <li>",
"       After surgical removal of the ovaries, chemotherapy, or radiation therapy of the pelvis for cancer.",
"      </li>",
"      <li>",
"       After having a baby, particularly if you breastfeed.",
"      </li>",
"      <li>",
"       While using certain medications, such as danazol, medroxyprogesterone (Provera&reg; or DepoProvera&reg;), leuprolide (Lupron&reg;), or nafarelin. When these medications are stopped, estrogen is produced normally again.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Women who smoke cigarettes have been shown to have an increased risk of an earlier menopause transition as compared to non-smokers. Therefore, atrophic vaginitis symptoms may appear at a younger age in this population.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      VAGINAL DRYNESS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There are two treatment options for women with vaginal dryness:",
"     <span class=\"nowrap\">",
"      moisturizers/lubricants",
"     </span>",
"     and vaginal estrogen. All vaginal dryness treatments work temporarily. The vaginal dryness will return when the treatment is stopped unless the ovaries make more estrogen.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Vaginal lubricants and moisturizers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Vaginal lubricants and moisturizers can be purchased without a prescription. These products do not contain any hormones and have virtually no side effects.",
"    </p>",
"    <p>",
"     Lubricants are designed to reduce friction and discomfort from dryness during sexual intercourse. The lubricant is applied inside the vagina or on the penis just before having sex. Products designed as vaginal lubricants (eg, Astroglide&reg;) are more effective than lubricants that are not designed for this purpose, such as petroleum jelly (Vaseline&reg;).",
"    </p>",
"    <p>",
"     Oil-based lubricants, such as petroleum jelly, baby oil, or mineral oil, may damage latex condoms",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     diaphragms and make them less effective in preventing pregnancy or sexually transmitted infections. Polyurethane condoms can be used with oil based products. Also, lubricants that are made with water or silicone can be used with latex condoms and diaphragms.",
"    </p>",
"    <p>",
"     Natural lubricants, such as olive, avocado or peanut oil, are easily available products that may be used as a lubricant with sex. Again, natural oils are not recommended for use with latex condoms or diaphragms; the oil can damage the latex, potentially making it less effective in preventing pregnancy or sexually transmitted infections.",
"    </p>",
"    <p>",
"     Vaginal moisturizes (eg, Replens&reg;, Moist Again&trade;, Vagisil&reg;, K-Y&reg; Silk-E&reg;, and Feminease&reg;) are formulated to allow water to be retained in the vaginal tissues. Moisturizers are applied into the vagina three times weekly to allow a continued moisturizing effect. These should not be used just before having sex, as they can be irritating.",
"    </p>",
"    <p>",
"     Hand and body lotions should not be used to relieve vaginal dryness since they can be irritating to the vaginal tissues.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Vaginal estrogen",
"     </span>",
"     &nbsp;&mdash;&nbsp;Vaginal estrogen is the most effective treatment option for women with vaginal dryness. Vaginal estrogen must be prescribed by a healthcare provider.",
"    </p>",
"    <p>",
"     Very low doses of vaginal estrogen can be used when it is put into the vagina to treat vaginal dryness. A small amount of estrogen is absorbed into the bloodstream, but only about 100 times less than when using estrogen pills or tablets. As a result, there is a much lower risk of side effects, such as blood clots, breast cancer, and heart attack, compared with other estrogen-containing products (birth control pills, menopausal hormone therapy).",
"    </p>",
"    <p>",
"     Several types of vaginal estrogen products are available:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Estrogen cream (eg, Premarin&reg;, Estrace&reg; cream) is inserted into the vagina every day for two to three weeks, and then one or two times weekly. The cream can be difficult to measure accurately and insert into the vagina.",
"      </li>",
"      <li>",
"       The vaginal estrogen tablet (Vagifem&reg;) is a small tablet that is inserted inside the vagina. The tablet is packaged in a disposable applicator. Vagifem is usually taken every day for two weeks and then twice weekly.",
"      </li>",
"      <li>",
"       The vaginal estrogen ring, called Estring&reg;, is a flexible plastic ring that is worn inside the vagina all the time. It is replaced every three months by the woman or her healthcare provider. The ring does not need to be removed during sex or bathing. It cannot be felt by most women or their sexual partners. In women who have previously had a hysterectomy, the ring will sometimes fall out.",
"       <br/>",
"       Estring&reg; should not be confused with the estrogen replacement vaginal ring (Femring&reg;), which releases a much higher dose of estrogen and is intended to be absorbed into the body to relieve hot flashes. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"        \"Patient information: Postmenopausal hormone therapy (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      How long can I use vaginal estrogen?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Vaginal estrogen is thought to be safe and can probably be used indefinitely, although there are no long-term studies confirming its safety.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Is vaginal estrogen safe for women with a history of breast cancer?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The safety of vaginal estrogen in women who have a past history of breast cancer is unclear. A small amount of estrogen can be absorbed from the vagina into the bloodstream. If you have a history of breast cancer, talk to your healthcare provider or your oncologist about the potential risks and benefits of vaginal estrogen.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Sexual activity",
"     </span>",
"     &nbsp;&mdash;&nbsp;Vaginal estrogen improves vaginal dryness quickly, usually within a few weeks. You may continue to have sex as you treat vaginal dryness because sex itself can help to keep the vaginal tissues healthy. Sexual activity (including masturbation) may help the vaginal tissues by keeping them soft and stretchable and preventing the tissues from shrinking.",
"    </p>",
"    <p>",
"     If sex continues to be painful despite treatment for vaginal dryness, talk to your healthcare provider. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23128?source=see_link\">",
"      \"Differential diagnosis of sexual pain in women\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413361311\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11566853\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/12/23747?source=see_link\">",
"      Patient information: Uterine cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=see_link\">",
"      Patient information: Sex problems in women (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/2/13346?source=see_link\">",
"      Patient information: Atrophic vaginitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/60/43970?source=see_link\">",
"      Patient information: Dyspareunia (painful sex) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/34/547?source=see_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/33/36370?source=see_link\">",
"      Patient information: Vulvar pain (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11566887\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37876?source=see_link\">",
"      Desquamative inflammatory vaginitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=see_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=see_link\">",
"      Clinical manifestations and diagnosis of vaginal atrophy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=see_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23128?source=see_link\">",
"      Differential diagnosis of sexual pain in women",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information [",
"     <a class=\"abstract\" href=\"UTD.htm?7/23/7537/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/002142.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/002142.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/menopause.cfm\">",
"      www.hormone.org/public/menopause.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?7/23/7537?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7537/abstract/1\">",
"      North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012; 19:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7537/abstract/2\">",
"      Bachmann G, Lobo RA, Gut R, et al. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008; 111:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7537/abstract/3\">",
"      Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95:s1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f7_23_7537=[""].join("\n");
var outline_f7_23_7537=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           VAGINAL DRYNESS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           VAGINAL DRYNESS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           VAGINAL DRYNESS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f7_23_7538="Scalp lac hemorrhage";
var content_f7_23_7538=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Treatment of scalp laceration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 529px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A circumferential penrose drain provides temporary control of hemorrhage while staple closure is performed on a large scalp laceration.",
"    <br>",
"     Inset: Alternatively, Raney clips may be placed along the wound margin for hemorrhage control.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_23_7538=[""].join("\n");
var outline_f7_23_7538=null;
var title_f7_23_7539="Phenazopyridine: Pediatric drug information";
var content_f7_23_7539=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenazopyridine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/7/41075?source=see_link\">",
"    see \"Phenazopyridine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/44/11972?source=see_link\">",
"    see \"Phenazopyridine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AZO Standard&reg; Maximum Strength [OTC] [DSC];",
"     </li>",
"     <li>",
"      AZO Standard&reg; [OTC] [DSC];",
"     </li>",
"     <li>",
"      AZO Urinary Pain Relief&trade; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      AZO Urinary Pain Relief&trade; [OTC];",
"     </li>",
"     <li>",
"      Azo-Gesic&trade; [OTC];",
"     </li>",
"     <li>",
"      Baridium [OTC];",
"     </li>",
"     <li>",
"      Phenazo [OTC];",
"     </li>",
"     <li>",
"      Pyridium&reg;;",
"     </li>",
"     <li>",
"      Urinary Pain Relief [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Urinary",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Local Anesthetic, Urinary",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/7/41075?source=see_link\">",
"      see \"Phenazopyridine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 12 mg/kg/day in 3 divided doses for 2 days if used concomitantly with an antibacterial agent for UTI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 95-200 mg 3-4 times/day for 2 days if used concomitantly with an antibacterial agent for UTI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-80 mL/minute: Administer every 8-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Avoid use",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F208682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 100 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AZO Standard&reg;: 95 mg [DSC] [gluten free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AZO Standard&reg; Maximum Strength: 97.5 mg [DSC] [gluten free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AZO Urinary Pain Relief&trade;: 95 mg [gluten free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AZO Urinary Pain Relief&trade; Maximum Strength: 97.5 mg [gluten free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Azo-Gesic&trade;: 95 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Baridium: 97.2 mg [contains sodium 0.184 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenazo: 95 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pyridium&reg;: 100 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Urinary Pain Relief: 95 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F208668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food to decrease GI distress",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of urinary burning, itching, frequency and urgency in association with urinary tract infection, or following urologic procedures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F208727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Phenazopyridine may be confused with phenoxybenzamine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pyridium&reg; may be confused with Dyrenium&reg;, Perdiem&reg;, pyridoxine, pyrithione",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F208725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Stomach cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal failure, hemolytic anemia, hepatitis, methemoglobinemia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenazopyridine or any component; liver or kidney disease (do not use in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-80 mL/minute)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Does not treat infection, acts only as an analgesic; drug should be discontinued if skin or sclera develop a yellow color.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F208677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F208679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13801080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phenazopyridine crosses the placenta. Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exerts local topical anesthetic or analgesic action on urinary tract mucosa through an unknown mechanism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver and other tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine (where it exerts its action); renal excretion (as unchanged drug) is rapid and accounts for 65% of the drug's elimination",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/44/11972?source=see_link\">",
"      see \"Phenazopyridine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May discolor urine orange or red; may stain contact lenses and fabric; not an antibiotic and does not treat infection; contact physician for antibiotic therapy",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12697 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_23_7539=[""].join("\n");
var outline_f7_23_7539=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208696\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060990\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060985\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208682\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208668\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060993\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060992\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208727\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208725\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060997\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060984\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060983\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299859\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208677\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208679\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13801080\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060982\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060996\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060989\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12697\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12697|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/7/41075?source=related_link\">",
"      Phenazopyridine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/44/11972?source=related_link\">",
"      Phenazopyridine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_23_7540="Complex atherosclerotic plaque in the thoracic aorta";
var content_f7_23_7540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complex atherosclerotic plaque in the thoracic aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 584px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Complex atherosclerotic plaque in the thoracic aorta visualized by 2D TEE.",
"    <br>",
"     (A) Ulcerated plaque in the aortic arch.",
"     <br>",
"      (B) Plaque with a mobile component representing superimposed thrombus (arrow) in the descending thoracic aorta.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Dr. Muhamed Saric.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_23_7540=[""].join("\n");
var outline_f7_23_7540=null;
var title_f7_23_7541="Colon and rectal cancer screening";
var content_f7_23_7541=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Colon and rectal cancer screening (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/23/7541/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7541/contributors\" id=\"au323\">",
"       Robert H Fletcher, MD, MSc",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/23/7541/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7541/contributors\" id=\"se4549\">",
"       Kenneth K Tanabe, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/23/7541/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7541/contributors\" id=\"de162\">",
"       H Nancy Sokol, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?7/23/7541?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      COLON CANCER SCREENING OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Colorectal cancer is a cancer that develops in the large intestine [colon] or rectum. The primary goal of colon cancer screening is to prevent deaths from colon cancer. Screening tests can help identify cancers at an early and potentially treatable stage. Some tests can also prevent the development of colorectal cancer by identifying precancerous abnormal growths called adenomatous polyps, which can be removed before they become malignant.",
"    </p>",
"    <p>",
"     All adults should undergo colon cancer screening beginning at age 50 or earlier, depending upon their risk of developing colorectal cancer. Several tests are currently available, each of which has advantages and disadvantages. The optimal screening test depends upon your preferences and your risk of developing colon cancer.",
"    </p>",
"    <p>",
"     This article discusses colon cancer risks, available screening tests, and recommendations for screening based upon your risks. There are additional topics about the screening tests themselves (see",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"      \"Patient information: Flexible sigmoidoscopy (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"      \"Patient information: Colonoscopy (Beyond the Basics)\"",
"     </a>",
"     ) as well as about particular conditions (see",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=see_link\">",
"      \"Patient information: Colon polyps (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"      \"Patient information: Crohn's disease (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"      \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      EFFECTIVENESS OF COLON CANCER SCREENING",
"     </span>",
"    </p>",
"    <p>",
"     Most colorectal cancers develop from precancerous polyps. Polyps are growths that arise in the lining of the colon and are visible when the bowel is examined by endoscopy (colonoscopy or sigmoidoscopy). There are two types of polyps: adenomatous and hyperplastic. Adenomatous polyps can become cancerous over time; this progression takes at least 10 years in most people.",
"    </p>",
"    <p>",
"     Colon cancer screening tests work by detecting polyps or by finding early stage cancers. Regular screening for and removal of polyps reduces your risk of developing colorectal cancer - by up to 90 percent with colonoscopy. Early detection of cancers that are already present in the colon increases the chances of successful treatment and decreases the chance of dying as a result of the cancer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      COLON CANCER RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Several factors increase an individual's risk of developing colorectal cancer. Having one or more of these factors will determine the age when you should begin screening, the frequency of screening, and the screening tests that are most appropriate.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Factors that increase risk",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several characteristics increase the risk of colorectal cancer. While each individual risk factor adds some risk, risk is substantially increased if several are present together.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Family history of colorectal cancer &mdash; Having colorectal cancer in a family member increases your risk of cancer if the family member is a first degree relative (a parent, brother or sister, or child), if several family members are affected, or if the cancers occurred at an early age (eg, before age 55 years). (See",
"       <a class=\"local\" href=\"#H20\">",
"        'Family history of colorectal cancer'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Prior colorectal cancer or polyps &mdash; People who have previously had colorectal cancer have an increased risk of developing a new colorectal cancer. People who have had adenomatous polyps before the age of 60 years are also at increased risk for developing colorectal cancer. Screening recommendations for these groups are discussed separately. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=see_link\">",
"        \"Patient information: Colon polyps (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=see_link\">",
"        \"Patient information: Colon and rectal cancer (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Increasing age &mdash; Although the average person has a 5 percent lifetime risk of developing colorectal cancer, 90 percent of these cancers occur in people older than 50 years of age. Risk increases with age throughout life.",
"      </li>",
"      <li>",
"       Lifestyle factors &mdash; Several lifestyle factors increase the risk of colorectal cancer, including:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       A diet high in fat and red meat and low in fiber",
"      </li>",
"      <li>",
"       A sedentary lifestyle",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Large increase in risk",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some conditions greatly increase the risk of colorectal cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Familial adenomatous polyposis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Familial adenomatous polyposis (FAP) is an uncommon inherited condition that increases the risk of colorectal cancer. Nearly 100 percent of people with this condition will develop colorectal cancer during their lifetime, and most of these cancers occur before the age of 50 years. FAP causes hundreds of polyps to develop throughout the colon. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"      \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Hereditary nonpolyposis colon cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hereditary nonpolyposis colon cancer (HNPCC, also called Lynch syndrome) is another inherited condition associated with an increased risk of colorectal cancer. It is slightly more common than FAP, but is still uncommon, accounting for about 1 in 20 cases of colorectal cancer. About 70 percent of people with HNPCC will experience colorectal cancer by the age of 65. Cancer also tends to occur at younger ages. People with HNPCC are also at risk for other types of cancer, including cancer of the uterus, stomach, bladder, kidney, and ovary. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"      \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Inflammatory bowel disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with Crohn's disease of the colon or ulcerative colitis have an increased risk of colorectal cancer. The amount of increased risk depends upon the amount of inflamed colon and the duration of disease; pancolitis (inflammation of the entire colon) and colitis of 10 years' duration or longer are associated with the greatest risk for colorectal cancer. The risk of colon cancer is not increased in people with irritable bowel disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1683261246\">",
"     <span class=\"h2\">",
"      Factors that may decrease risk",
"     </span>",
"     &nbsp;&mdash;&nbsp;Factors that may decrease risk include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Calcium &mdash; Although a few studies have shown that people who have higher calcium intake also have a lower risk of colorectal cancer, it is not known if taking calcium supplements or eating a high calcium diet lowers the cancer risk.",
"      </li>",
"      <li>",
"       Aspirin, ibuprofen, and related nonsteroidal antiinflammatory medications may decrease the risk of developing colorectal cancer. However, there is not enough evidence that the benefits of aspirin or NSAIDs for cancer prevention outweigh the risks associated with side effects of the medicines. Aspirin can increase the risk for a hemorrhagic stroke or gastrointestinal bleeding, and NSAIDs are associated with increased risk for peptic ulcer, heart, and kidney disease.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      COLON CANCER SCREENING TESTS",
"     </span>",
"    </p>",
"    <p>",
"     Several tests are available for colorectal cancer screening, including tests that can detect cancers at an early treatable stage (eg, stool tests), and tests that also detect pre-cancerous polyps (adenomas) and can lead to cancer prevention.",
"    </p>",
"    <p>",
"     Guidelines from expert groups recommend that you and your healthcare provider discuss the available options and choose a testing strategy that makes sense for you. Tests that detect pre-cancerous polyps are preferable; these include colonoscopy, CT colonography, and flexible sigmoidoscopy. Stool tests that detect blood or abnormal DNA are another option [",
"     <a class=\"abstract\" href=\"UTD.htm?7/23/7541/abstract/1\">",
"      1",
"     </a>",
"     ]. Being screened with any test is more important than which test is used.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Colonoscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Colonoscopy allows a physician to see the lining of the rectum and the entire colon (",
"     <a class=\"graphic graphic_figure graphicRef58531 \" href=\"UTD.htm?12/60/13250\">",
"      figure 1",
"     </a>",
"     ). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"      \"Patient information: Colonoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Procedure &mdash; Colonoscopy requires that you prepare by cleaning out your entire colon and rectum. This usually involves consuming a liquid medication that causes temporary diarrhea. You are given a mild sedative drug before the procedure. During colonoscopy, a thin, lighted tube is used to directly view the lining of the rectum and the entire colon. Polyps and some cancers can be removed during this procedure.",
"      </li>",
"      <li>",
"       Effectiveness &mdash; Colonoscopy detects most small polyps and almost all large polyps and cancers [",
"       <a class=\"abstract\" href=\"UTD.htm?7/23/7541/abstract/2\">",
"        2",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       Risks and disadvantages &mdash; The risks of colonoscopy, while small, are greater than those of other screening tests. Colonoscopy may lead to serious bleeding or a tear of the intestinal wall in some individuals (about 1 in 1,000). Because the procedure usually requires sedation, you must be accompanied home after the procedure and you should not return to work or other activities on the same day.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Sigmoidoscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sigmoidoscopy allows a physician to directly view the lining of the rectum and the lower part of the colon (the descending colon) (",
"     <a class=\"graphic graphic_figure graphicRef58531 \" href=\"UTD.htm?12/60/13250\">",
"      figure 1",
"     </a>",
"     ). This area accounts for about one-half of the total area of the rectum and colon. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"      \"Patient information: Flexible sigmoidoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Procedure &mdash; Sigmoidoscopy requires that you prepare by cleaning out the lower bowel. This usually involves consuming a clear liquid diet and using an enema shortly before the examination. Most people do not need sedative drugs and are able to return to work or other activities the same day. During the procedure, a thin, lighted tube is advanced into the rectum and through the left side of the colon to check for polyps and cancer; the procedure may cause mild cramping. Biopsies (small samples of tissue) can be taken during sigmoidoscopy. Sigmoidoscopy may be performed in a doctor's office.",
"      </li>",
"      <li>",
"       Effectiveness &mdash; Sigmoidoscopy can identify polyps and cancers in the descending colon and rectum with a high degree of accuracy. Studies have shown that sigmoidoscopy reduces the incidence of colorectal cancer and overall mortality [",
"       <a class=\"abstract\" href=\"UTD.htm?7/23/7541/abstract/3\">",
"        3",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       Risks and disadvantages &mdash; The risks of sigmoidoscopy are small. The procedure creates a small tear in the intestinal wall in about 2 per every 10,000 people; death from this complication is rare. A major disadvantage of sigmoidoscopy is that it cannot detect polyps or cancers that are located in the right side of the colon.",
"      </li>",
"      <li>",
"       Additional testing &mdash; Finding polyps or cancers in the lower colon increase the likelihood that there are polyps or cancer in the remaining part of the colon. Thus, if sigmoidoscopy reveals polyps or cancer, colonoscopy is recommended to view the entire length of the colon.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4053849\">",
"     <span class=\"h2\">",
"      CT colonography (\"virtual colonoscopy\")",
"     </span>",
"     &nbsp;&mdash;&nbsp;Computed tomography colonography (CTC, sometimes called \"virtual colonoscopy\") is a test that uses a CT scanner to take images of the entire bowel. These images are in two- and three-dimensions, and are reconstructed to allow a radiologist to determine if polyps or cancers are present (",
"     <a class=\"graphic graphic_picture graphicRef72330 \" href=\"UTD.htm?1/26/1454\">",
"      picture 1",
"     </a>",
"     ). The major advantages of CTC are that it does not require sedation, it is non-invasive, the entire bowel can be examined, and abnormal areas (adenomas) can be detected about as well as with traditional (optical) colonoscopy.",
"    </p>",
"    <p>",
"     There are several disadvantages of CTC. Like traditional colonoscopy, CTC usually requires a bowel prep to clean out the colon. If an abnormal area is found with CTC, a traditional colonoscopy will be needed at a later time to see the area and take a tissue sample (biopsy). CTC may detect abnormalities other than polyps and colorectal cancer. Many of these incidental findings will require further testing. This test may not be covered by health insurance plans in the United States. CTC, like many other imaging tests, exposes patients to radiation which may have long-term risks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Stool tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Colorectal cancers often release microscopic amounts of blood and abnormal DNA into the stool. Stool tests can detect blood or abnormal DNA makers.",
"    </p>",
"    <p>",
"     Two types of tests, called guaiac tests (typically Hemoccult&reg;) and immunochemical tests, evaluate the stool for blood, which may be present if there is bleeding from a colon cancer (or other source of blood).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       With guaiac testing, you collect two samples of stool from three consecutive bowel movements, which you apply to home collection cards. You mail the cards back to the healthcare provider.",
"      </li>",
"      <li>",
"       With immunochemical testing, you use a long handled tool to brush the surface of your stool in the toilet. You apply the brush to a card, and then mail the card to a laboratory. You do not have to change your diet or stop any medications with this test.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Guaiac testing, when performed once per year, reduces the risk of dying from colorectal cancer by as much as one-third [",
"     <a class=\"abstract\" href=\"UTD.htm?7/23/7541/abstract/4\">",
"      4",
"     </a>",
"     ]. However, because polyps seldom bleed, guaiac testing is less likely to detect polyps than other screening tests. In addition, only 2 to 5 percent of people with a positive stool test actually have colorectal cancer. If the stool test is positive, your entire colon should be examined with colonoscopy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Fecal occult blood test and sigmoidoscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Combined screening with a fecal occult blood test (guaiac) and sigmoidoscopy is a possible screening strategy and may be more effective than either test done alone.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      COLON CANCER SCREENING PLANS",
"     </span>",
"    </p>",
"    <p>",
"     The recommended colon cancer screening plan depends upon your risk of colorectal cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Average risk of colorectal cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with an average risk of colorectal cancer should begin screening at age 50. One of the following screening strategies is recommended [",
"     <a class=\"abstract\" href=\"UTD.htm?7/23/7541/abstract/1\">",
"      1",
"     </a>",
"     ]:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Colonoscopy every 10 years",
"      </li>",
"      <li>",
"       Computed tomographic colonography every 5 years",
"      </li>",
"      <li>",
"       Flexible sigmoidoscopy every five years",
"      </li>",
"      <li>",
"       Stool testing every year (for guaiac and immunochemical occult blood tests)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Increased risk of colorectal cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Screening plans for people with an increased risk may entail screening at a younger age, more frequent screening,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     the use of more sensitive screening tests (usually colonoscopy). The optimal screening plan depends upon the reason for increased risk.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Family history of colorectal cancer",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       People who have one first-degree relative (parent, brother, sister, or child) with colorectal cancer or adenomatous polyps at a young age (before the age of 60 years), or two first-degree relatives diagnosed at any age, should begin screening for colon cancer earlier, typically at age 40, or 10 years younger than the earliest diagnosis in their family, whichever comes first. Screening usually includes colonoscopy, which should be repeated every five years.",
"       <br/>",
"       <br/>",
"       (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=see_link\">",
"        \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       People who have one first-degree relative (parent, brother, sister, or child) who has experienced colorectal cancer or adenomatous polyps at age 60 or later, or two or more second degree relatives (grandparent, aunt, uncle) with colorectal cancer should begin screening by colonoscopy at age 50, and screening should be repeated as for average risk people.",
"      </li>",
"      <li>",
"       People with a second-degree relative (grandparent, aunt, or uncle) or third-degree relative (great-grandparent or cousin) with colorectal cancer are considered to have an average risk of colorectal cancer (see",
"       <a class=\"local\" href=\"#H18\">",
"        'Average risk of colorectal cancer'",
"       </a>",
"       above).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Some people have known genetically-based colon cancer syndromes in their family, such as familial adenomatous polyposis (FAP) or hereditary nonpolyposis colon cancer (HNPCC). These less common conditions require aggressive screening and preventive treatments, and individuals with these conditions in their family should be managed by a clinician with clinical expertise in these syndromes. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"      \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link\">",
"      \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=see_link\">",
"      \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Inflammatory bowel disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with ulcerative colitis or Crohn's disease have an increased risk of colon cancer. The best screening plan depends upon how much of the colon is affected and how long you have had the disease. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"      \"Patient information: Crohn's disease (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"      \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link\">",
"      \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10049980\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10049987\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=see_link\">",
"      Patient information: Colon and rectal cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=see_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9298?source=see_link\">",
"      Patient information: Colon polyps (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/47/21234?source=see_link\">",
"      Patient information: Familial adenomatous polyposis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10050001\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"      Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=see_link\">",
"      Patient information: Colon polyps (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=see_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10050015\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link\">",
"      Colorectal cancer surveillance in inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36632?source=see_link\">",
"      Computed tomographic colonography",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7352?source=see_link\">",
"      Gardner syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=see_link\">",
"      Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=see_link\">",
"      Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.nci.nih.gov/\">",
"      www.nci.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.com/\">",
"      www.nccn.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-ACS-2345",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Gastroenterological Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.gastro.org/\">",
"      www.gastro.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American College of Gastroenterology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.acg.gi.org/\">",
"      www.acg.gi.org",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?7/23/7541?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7541/abstract/1\">",
"      Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008; 58:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7541/abstract/2\">",
"      Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997; 112:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7541/abstract/3\">",
"      Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7541/abstract/4\">",
"      Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328:1365.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f7_23_7541=[""].join("\n");
var outline_f7_23_7541=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           COLON CANCER SCREENING OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           EFFECTIVENESS OF COLON CANCER SCREENING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           COLON CANCER RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           COLON CANCER SCREENING TESTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           COLON CANCER SCREENING PLANS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/60/13250\" title=\"figure 1\">",
"           Diagram colon rectum PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/26/1454\" title=\"picture 1\">",
"           Polyp colonoscopy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f7_23_7542="Treatment of low-risk endometrial cancer";
var content_f7_23_7542=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of low-risk endometrial cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/23/7542/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7542/contributors\">",
"     Steven C Plaxe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7542/contributors\">",
"     Arno J Mundt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/23/7542/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7542/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/23/7542/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7542/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/23/7542/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with low-risk endometrial cancer have an excellent prognosis following surgery; therefore adjuvant therapy is not generally recommended. This review will focus on the options for adjuvant treatment in endometrial cancer and will explain why it is not recommended for women with low-risk disease. The treatment of intermediate- and high-risk endometrial cancers is discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=see_link\">",
"       \"Approach to adjuvant treatment of endometrial cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13287?source=see_link\">",
"       \"Adjuvant treatment of intermediate-risk endometrial cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41991?source=see_link\">",
"       \"Adjuvant treatment of high-risk endometrial cancers\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18825003\">",
"    <span class=\"h1\">",
"     DEFINITION OF LOW RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-risk endometrial cancer is defined as (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36983?source=see_link\">",
"     \"Endometrial carcinoma: Histopathology and pathogenesis\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histologic grade 1 or 2",
"     </li>",
"     <li>",
"      Cancer limited to the endometrium (a subset of stage IA disease) (",
"      <a class=\"graphic graphic_table graphicRef66382 \" href=\"UTD.htm?4/19/4413\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cancer that is not a high-risk histologic type (eg, clear cell, serous, or carcinosarcoma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with low-risk endometrial cancer who did not undergo nodal evaluation are considered unstaged, but given that their risk of nodal involvement is less than five percent, we suggest not performing surgical staging in this population (if not done as part of the primary surgery). Nodal evaluation of endometrial cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link&amp;anchor=H9#H9\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\", section on 'Lymph node evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not exclude women with cancer that involves the lower uterine segment in the low-risk group, although some experts do. While lower uterine segment involvement appears to be associated with worse survival outcomes, it may be due to the strong association of lower uterine segment involvement with lymph node involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7542/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In this topic, women with lower uterine segment involvement are included in the low-risk disease population. This differs slightly from the guidelines of the National Comprehensive Cancer Network (NCCN) in which involvement of the lower uterine segment is considered as part of the group with intermediate-risk endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7542/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367295881\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend a hysterectomy for all women with newly diagnosed endometrial cancer. However, women who desire fertility preservation may be candidates for medical therapy (see",
"    <a class=\"local\" href=\"#H189464954\">",
"     'Women desiring preservation of fertility'",
"    </a>",
"    below). Our initial approach is to perform a total extrafascial hysterectomy with bilateral salpingo-oophorectomy via laparotomy or by a minimally invasive technique. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18825294\">",
"    <span class=\"h1\">",
"     ADJUVANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following surgery, the primary risk in patients with low-risk endometrial cancer is for local recurrence (eg, at the vaginal vault). However, the risk is &le;5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7542/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Therefore, we do not recommend adjuvant therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While radiation therapy can reduce the risk of local recurrence, it does not improve overall survival (see",
"      <a class=\"local\" href=\"#H200482556\">",
"       'Radiation therapy'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Given the low risk for distant metastases, chemotherapy also has no role for adjuvant treatment and exposes these women to excessive and unnecessary toxicity.",
"     </li>",
"     <li>",
"      Progestin therapy plays no role in the adjuvant setting. However, it is an alternative to immediate hysterectomy for women who wish to preserve their fertility (see",
"      <a class=\"local\" href=\"#H189467855\">",
"       'Progestin therapy'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H189464954\">",
"       'Women desiring preservation of fertility'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following evidence supports the lack of benefit of adjuvant therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H200482556\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) can be delivered as pelvic RT or vaginal brachytherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H200483637\">",
"    <span class=\"h3\">",
"     Pelvic radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic RT utilizes an external source for RT. Radiographs are used to design the treatment field that encompasses the region of interest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22570?source=see_link\">",
"     \"Overview of radiation therapy for gynecologic malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women with low-risk endometrial cancer, the risk for metastatic disease (particularly for a local recurrence) is &le;5 percent. Therefore, there is no indication for pelvic RT to reduce the risk of recurrence. In addition, there are data that suggest pelvic RT may worsen survival.",
"   </p>",
"   <p>",
"    In a 2012 meta-analysis of eight trials that evaluated RT for stage I endometrial cancer, among women with low-risk endometrial cancer (n=517), RT was associated with an increased risk of death related to endometrial cancer compared to observation (relative risk, 2.64, 95% CI 1.05-6.66) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7542/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H200483652\">",
"    <span class=\"h3\">",
"     Vaginal brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal brachytherapy is a local application of radiation that aims to deliver precise doses of radiation to the target tissue while sparing the surrounding normal tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22570?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of radiation therapy for gynecologic malignancies\", section on 'Brachytherapy'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    For women with low-risk endometrial cancer, there is no benefit of vaginal brachytherapy in terms of survival or reducing the risk of locoregional recurrence.",
"   </p>",
"   <p>",
"    In a multi-institutional European study, 645 women with grade 1 to 2 endometrioid endometrial cancer invading less than half of the myometrium [surgical stage IA (",
"    <a class=\"graphic graphic_table graphicRef66382 \" href=\"UTD.htm?4/19/4413\">",
"     table 1",
"    </a>",
"    )] were allocated to either surgical treatment alone or to surgery plus vaginal brachytherapy (3 to 8 Gy administered in three to six fractions over 4 to 15 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7542/abstract/11\">",
"     11",
"    </a>",
"    ]. There were no differences in cancer-specific or overall survival. However, vaginal brachytherapy was associated with an increase in genitourinary symptoms (eg, dysuria, frequency, incontinence) (2.8 versus 0.6 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189467855\">",
"    <span class=\"h2\">",
"     Progestin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because endometrial cancer is associated with excess estrogen production, progestin therapy has been used as an adjuvant treatment. However, we do not recommend adjuvant progestin therapy for women with low-risk endometrial cancer. In a meta-analysis of four trials, there was no difference in the risk of death at five years between adjuvant progestin therapy compared to no further treatment (relative risk, 1.00, 95% CI 0.85-1.18) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7542/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of progestins rather than immediate hysterectomy in women of child-bearing potential is discussed below. (See",
"    <a class=\"local\" href=\"#H189464954\">",
"     'Women desiring preservation of fertility'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189464954\">",
"    <span class=\"h1\">",
"     WOMEN DESIRING PRESERVATION OF FERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with histologically confirmed grade 1 or 2 endometrial cancer that appears superficially or minimally invasive, medical treatment with progestins is reasonable if fertility preservation is desired. However, if there is imaging evidence of deep myometrial invasion (ie, &gt;50 percent), we suggest hysterectomy rather than medical therapy because deep myometrial invasion may signify the presence of a more aggressive cancer. Ultimately, the treatment approach must be individualized based on the woman&rsquo;s desires and the risks and benefits of medical treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=see_link&amp;anchor=H1596994160#H1596994160\">",
"     \"Approach to adjuvant treatment of endometrial cancer\", section on 'Risk stratification and overview of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to medical therapy, a thorough screening evaluation, including transvaginal ultrasonography and a contrast enhanced MRI of the uterus, is necessary to define whether there is evidence of myometrial invasion and to evaluate the extent of tumor involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7542/abstract/13\">",
"     13",
"    </a>",
"    ]. While the optimal surveillance method for following patients treated with progestins is unknown, repeat pelvic ultrasound with endometrial biopsy every three months is a reasonable approach.",
"   </p>",
"   <p>",
"    Following completion of childbearing, we recommend surgical treatment, even in cases with demonstrated tumor regression, since many have ongoing risk factors for endometrial cancer (eg, obesity, chronic anovulation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link&amp;anchor=H6#H6\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\", section on 'Staging and primary surgical treatment'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Women should be counselled that despite this evaluation, there is a 15 to 30 percent risk that their disease is more aggressive than is suggested by endometrial biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7542/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In addition, there is a risk of disease progression despite medical therapy.",
"   </p>",
"   <p>",
"    The risks and benefits of fertility preservation were illustrated in a meta-analysis of 45 studies and 391 patients, 72 percent with grade 1 endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7542/abstract/16\">",
"     16",
"    </a>",
"    ]. The majority (74 percent) were treated with either medroxyprogesterone or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    with the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of complete response was 78 percent with a median time to response of six months.",
"     </li>",
"     <li>",
"      The spontaneous pregnancy rate was 36 percent.",
"     </li>",
"     <li>",
"      The rate of recurrence was 25 percent with a median time to recurrence of 24 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2001186911\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    (160",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    as initial treatment for women with low-risk endometrial cancer who desire fertility preservation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7542/abstract/17\">",
"     17",
"    </a>",
"    ]. Both oral and parenteral routes for progestin therapy appear to be effective, although the optimal dose and duration of therapy are unknown. The minimum duration of progestin therapy appears to be three months, but some women will require a longer course [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7542/abstract/18\">",
"     18",
"    </a>",
"    ]. After induction of response, we suggest periodic withdrawal of progestins.",
"   </p>",
"   <p>",
"    Other modalities, including IUDs and gonadotropin releasing hormone agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/11/9398?source=see_link\">",
"     triptorelin",
"    </a>",
"    ), have been tried. However, we do not recommend administering them in routine clinical practice until more data are available [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7542/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189464961\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with low-risk endometrial cancer have an excellent prognosis with a low recurrence risk and expected survival of &ge;90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7542/abstract/11,22\">",
"     11,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=see_link&amp;anchor=H4679282#H4679282\">",
"     \"Overview of endometrial carcinoma\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttreatment surveillance for women with endometrial cancer is the same regardless of risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=see_link&amp;anchor=H11157097#H11157097\">",
"     \"Overview of endometrial carcinoma\", section on 'Posttreatment surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/55/19314?source=see_link\">",
"       \"Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/12/8388?source=see_link\">",
"       \"Patient information: Endometrial cancer treatment after surgery (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After surgical and pathologic staging, women are defined as low-risk disease if their tumor is of low grade (1 or 2), confined to the endometrium (a subset of stage IA disease,), and is not a high-risk histologic type (eg, clear cell, serous, or carcinosarcoma). (See",
"      <a class=\"local\" href=\"#H18825003\">",
"       'Definition of low risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with newly diagnosed endometrial cancer, we recommend a hysterectomy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Our initial approach is to perform a total extrafascial hysterectomy with bilateral salpingo-oophorectomy via laparotomy or by a minimally invasive technique. The risk for women with low-risk endometrial cancer is primarily for a local recurrence (eg, at the vaginal vault) following surgery. However, the risk is &le;5 percent following surgical treatment alone. (See",
"      <a class=\"local\" href=\"#H367295881\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with surgically and pathologically defined low-risk endometrial cancer, we recommend not administering adjuvant therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18825294\">",
"       'Adjuvant therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For young women with endometrial cancer (diagnosed by dilatation and curettage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      endometrial biopsy) who wish to preserve their fertility, treatment with progestins is reasonable, provided there is no imaging evidence of deep myometrial invasion. However, if there is imaging evidence of deep myometrial invasion, we prefer not to manage endometrial cancer with medical therapy, because this may signify a more aggressive cancer. (See",
"      <a class=\"local\" href=\"#H189464954\">",
"       'Women desiring preservation of fertility'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The treatment approach must be individualized based on the woman&rsquo;s desires and the risks and benefits of medical treatment. For women who choose medical therapy for endometrial cancer (see",
"      <a class=\"local\" href=\"#H2001186911\">",
"       'Medical therapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      for at least three months (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Women should undergo serial monitoring with pelvic ultrasound and endometrial biopsy every three months while on medical therapy. &nbsp;",
"     </li>",
"     <li>",
"      We recommend a hysterectomy following completion of family planning (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/1\">",
"      Madom LM, Brown AK, Lui F, et al. Lower uterine segment involvement as a predictor for lymph node spread in endometrial carcinoma. Gynecol Oncol 2007; 107:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/2\">",
"      Kizer NT, Gao F, Guntupalli S, et al. Lower uterine segment involvement is associated with poor outcomes in early-stage endometrioid endometrial carcinoma. Ann Surg Oncol 2011; 18:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/3\">",
"      Brown AK, Madom L, Moore R, et al. The prognostic significance of lower uterine segment involvement in surgically staged endometrial cancer patients with negative nodes. Gynecol Oncol 2007; 105:55.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelnes): Uterine neoplasms. Version 2.2012. file://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf (Accessed on December 09, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/5\">",
"      Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991; 40:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/6\">",
"      Eifel PJ, Ross J, Hendrickson M, et al. Adenocarcinoma of the endometrium. Analysis of 256 cases with disease limited to the uterine corpus: treatment comparisons. Cancer 1983; 52:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/7\">",
"      Orr JW Jr, Holimon JL, Orr PF. Stage I corpus cancer: is teletherapy necessary? Am J Obstet Gynecol 1997; 176:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/8\">",
"      Straughn JM Jr, Huh WK, Kelly FJ, et al. Conservative management of stage I endometrial carcinoma after surgical staging. Gynecol Oncol 2002; 84:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/9\">",
"      Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/10\">",
"      Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev 2012; 3:CD003916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/11\">",
"      Sorbe B, Nordstr&ouml;m B, M&auml;enp&auml;&auml; J, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer 2009; 19:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/12\">",
"      Martin-Hirsch PP, Bryant A, Keep SL, et al. Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev 2011; :CD001040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/13\">",
"      Kinkel K, Kaji Y, Yu KK, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology 1999; 212:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/14\">",
"      Eltabbakh GH, Shamonki J, Mount SL. Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors. Gynecol Oncol 2005; 99:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/15\">",
"      Leitao MM Jr, Kehoe S, Barakat RR, et al. Comparison of D&amp;C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 2009; 113:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/16\">",
"      Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012; 125:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/17\">",
"      Mazzon I, Corrado G, Masciullo V, et al. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril 2010; 93:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/18\">",
"      Gotlieb WH, Beiner ME, Shalmon B, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol 2003; 102:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/19\">",
"      Montz FJ, Bristow RE, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002; 186:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/20\">",
"      Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol 2005; 97:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/21\">",
"      Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 2003; 80:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7542/abstract/22\">",
"      Fung-Kee-Fung M, Dodge J, Elit L, et al. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 2006; 101:520.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3223 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-956556EC73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_23_7542=[""].join("\n");
var outline_f7_23_7542=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18825003\">",
"      DEFINITION OF LOW RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H367295881\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18825294\">",
"      ADJUVANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H200482556\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H200483637\">",
"      - Pelvic radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H200483652\">",
"      - Vaginal brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H189467855\">",
"      Progestin therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189464954\">",
"      WOMEN DESIRING PRESERVATION OF FERTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2001186911\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189464961\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3223\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3223|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/19/4413\" title=\"table 1\">",
"      Staging endometrial cancer I",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41991?source=related_link\">",
"      Adjuvant treatment of high-risk endometrial cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13287?source=related_link\">",
"      Adjuvant treatment of intermediate-risk endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=related_link\">",
"      Approach to adjuvant treatment of endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36983?source=related_link\">",
"      Endometrial carcinoma: Histopathology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=related_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=related_link\">",
"      Overview of endometrial carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22570?source=related_link\">",
"      Overview of radiation therapy for gynecologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/55/19314?source=related_link\">",
"      Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/12/8388?source=related_link\">",
"      Patient information: Endometrial cancer treatment after surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_23_7543="AUDIT questionnaire PI";
var content_f7_23_7543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F54903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F54903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    The alcohol use disorders identification test: Self-report version",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 1102px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_23_7543=[""].join("\n");
var outline_f7_23_7543=null;
var title_f7_23_7544="Evaluation of acute decompensated heart failure";
var content_f7_23_7544=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of acute decompensated heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/23/7544/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7544/contributors\">",
"     Duane S Pinto, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7544/contributors\">",
"     Stanley Lewis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/23/7544/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7544/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/23/7544/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7544/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/23/7544/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute decompensated heart failure (ADHF) is a common and potentially fatal cause of acute respiratory distress. Heart failure may be new or an exacerbation of chronic disease. The clinical syndrome is characterized by the development of acute dyspnea associated with the rapid accumulation of fluid within the lung's interstitial and alveolar spaces, which is the result of elevated cardiac filling pressures (cardiogenic pulmonary edema) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/1\">",
"     1",
"    </a>",
"    ]. ADHF can also present as elevated left sided filling pressures and dyspnea without pulmonary edema.",
"   </p>",
"   <p>",
"    ADHF is most commonly due to left ventricular (LV) systolic or diastolic dysfunction, with or without additional cardiac pathology, such as coronary artery disease or valve abnormalities. However, a variety of conditions or events can cause cardiogenic pulmonary edema in the absence of heart disease, including primary fluid overload (eg, due to blood transfusion), severe hypertension, renal artery stenosis, and severe renal disease.",
"   </p>",
"   <p>",
"    Noncardiogenic pulmonary edema is a distinct clinical syndrome associated with diffuse filling of the alveolar spaces in the absence of elevated pulmonary capillary wedge pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/1\">",
"     1",
"    </a>",
"    ]. Focused history, physical examination, echocardiography, laboratory analysis and, in some cases, direct measurement of pulmonary capillary wedge pressure can be used to distinguish cardiogenic from noncardiogenic pulmonary edema, as well as from other causes of acute respiratory distress. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=see_link\">",
"     \"Noncardiogenic pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Flash pulmonary edema is a term that is used to describe a particularly dramatic form of ADHF. In flash pulmonary edema the underlying pathophysiologic principles, etiologic triggers, and initial management strategies are similar to those of less severe ADHF, although there is a greater degree of urgency to the implementation of initial therapies and the search for triggering causes. (See",
"    <a class=\"local\" href=\"#H22643398\">",
"     'Flash pulmonary edema'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    General issues related to the diagnosis of ADHF will be reviewed here. The pathophysiology, etiology and treatment of ADHF and the evaluation of the clinically stable patient with suspected heart failure (HF) are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28503?source=see_link\">",
"     \"Pathophysiology of cardiogenic pulmonary edema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute decompensated HF is diagnosed using a constellation of clinical symptoms and signs. The diagnostic approach described here is in general agreement with the 2010 Heart Failure Society of America (HFSA) guidelines for ADHF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/2\">",
"     2",
"    </a>",
"    ], the 2009 focused update of the 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    HF guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/3\">",
"     3",
"    </a>",
"    ], the 2008 European Society of Cardiology (ESC) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/4\">",
"     4",
"    </a>",
"    ], and the 2006 Canadian Cardiovascular Society consensus conference recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ADHF most commonly present with complaints of cough, dyspnea and fatigue, which rapidly become more severe, and which may or may not be associated with chest discomfort. Heart failure may be new or an exacerbation of chronic disease.",
"   </p>",
"   <p>",
"    Initial assessment should include a brief, focused, history and physical examination to evaluate signs and symptoms of HF as well as potential contributing factors and comorbidities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28503?source=see_link\">",
"     \"Pathophysiology of cardiogenic pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients are typically tachypneic and may be using accessory muscles to breathe.",
"     </li>",
"     <li>",
"      Chest examination usually reveals crackles indicative of interstitial pulmonary edema and some patients have wheezing (called cardiac asthma). Cardiac asthma is present in as many as one-third of elderly patients presenting with dyspnea due to heart failure and is associated with greater hypercapnia but similar mortality rates [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients may have a tachycardia and are often hypertensive.",
"     </li>",
"     <li>",
"      Adequacy of systemic perfusion should be assessed. Hypotension, if present, may indicate severe ventricular dysfunction and impending cardiogenic shock. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=see_link\">",
"       \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Examination of the heart may reveal the presence of an S3 or S4 or both (summation gallop) and a new or changed murmur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"       \"Auscultation of cardiac murmurs\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"       \"Auscultation of heart sounds\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Volume status should be evaluated. Elevated jugular venous pressure may reflect elevated right-sided filling pressures from right or left heart dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link\">",
"       \"Examination of the jugular venous pulse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Examination of the extremities is usually normal, but may reveal evidence of peripheral edema if the patient has a history of chronic heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Identification of precipitating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 Heart Failure Society of America (HFSA) guidelines and the 2009",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    focused update recommended that patients admitted with ADHF undergo evaluation for potential precipitating factors including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adherence and process of care issues:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dietary indiscretion",
"     </li>",
"     <li>",
"      Nonadherence to medications",
"     </li>",
"     <li>",
"      Iatrogenic volume overload",
"     </li>",
"     <li>",
"      Significant drug interactions and side effects such as recent addition of negative inotropic drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , beta blockers) or nonsteroidal anti-inflammatory agents (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=see_link\">",
"       \"Drugs that should be avoided or used with caution in patients with heart failure\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Myocardial infarction and myocardial ischemia. Patients with ADHF commonly have coronary artery disease with or without an acute coronary syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/7\">",
"       7",
"      </a>",
"      ]. Patients should be monitored for signs and symptoms of ongoing ischemia. If acute coronary syndrome is suspected, serial ECGs and measurements of cardiac enzymes should be performed and urgent coronary angiography should be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"       \"Criteria for the diagnosis of acute myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H12\">",
"       'Coronary angiography'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Valvular disease (eg, acute or progressive mitral regurgitation)",
"     </li>",
"     <li>",
"      Atrial fibrillation and other arrhythmias (sinus tachycardia, atrial flutter, other supraventricular tachycardias, ventricular tachycardia). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link\">",
"       \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Progression of underlying cardiac dysfunction.",
"     </li>",
"     <li>",
"      Stress-induced (takotsubo) cardiomyopathy (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link\">",
"       \"Stress-induced (takotsubo) cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiotoxic agents such as alcohol, cocaine, and certain chemotherapy drugs.",
"     </li>",
"     <li>",
"      Right ventricular pacing, which produces dyssynchrony.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noncardiac",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severe hypertension, which is common in patients with ADHF (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=see_link\">",
"       \"Epidemiology and causes of heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29031?source=see_link\">",
"       \"Treatment of hypertension in patients with heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28503?source=see_link&amp;anchor=H15061766#H15061766\">",
"       \"Pathophysiology of cardiogenic pulmonary edema\", section on 'Renovascular hypertension'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Renal failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"       \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Miscellaneous factors such as anemia, hypo- or hyperthyroidism, fever, infection (eg, pneumonia), and uncontrolled diabetes.",
"     </li>",
"     <li>",
"      Pulmonary emboli. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22643398\">",
"    <span class=\"h3\">",
"     Flash pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flash pulmonary edema is a dramatic form of ADHF in which acute increases in left ventricular diastolic pressure, often associated with chronic elevation of diastolic filling pressures, cause rapid fluid accumulation in the pulmonary interstitium and alveolar spaces. Flash pulmonary edema may develop in some patients with myocardial ischemia with or without myocardial infarction, acute severe mitral regurgitation, hypertensive crisis, acute aortic regurgitation and stress-induced (takotsubo) cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33446?source=see_link\">",
"     \"Treatment of acute decompensated heart failure in acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=see_link\">",
"     \"Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of specific hypertensive emergencies\", section on 'Acute pulmonary edema'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=see_link\">",
"     \"Acute aortic regurgitation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link\">",
"     \"Stress-induced (takotsubo) cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with bilateral renal artery stenosis are at increased risk for developing flash pulmonary edema; this association was first described by Pickering et al. [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/8\">",
"     8",
"    </a>",
"    ] It has been named the Pickering syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/9\">",
"     9",
"    </a>",
"    ] and is an indication for renal artery revascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28503?source=see_link\">",
"     \"Pathophysiology of cardiogenic pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG may identify underlying predisposing or precipitating conditions for heart failure such as left ventricular hypertrophy, left atrial abnormalities, myocardial ischemia or infarction, or the presence of atrial fibrillation (",
"    <a class=\"graphic graphic_waveform graphicRef64381 \" href=\"UTD.htm?39/33/40471\">",
"     waveform 1",
"    </a>",
"    ). Acute coronary syndrome precipitating ADHF should be promptly identified by electrocardiogram and cardiac troponin testing and treated as appropriate for the condition and prognosis of the patient with consideration of coronary angiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link\">",
"     \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H12\">",
"     'Coronary angiography'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additional ECG abnormalities may be seen in a patient during an episode of ADHF. These include giant negative T waves, global T wave inversions, and marked QT interval prolongation. These changes may represent ischemia, which can be the cause or the result of the pulmonary edema. They can also be seen in patients with pulmonary edema due to noncoronary events, such as cerebrovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25271?source=see_link\">",
"     \"Neurogenic pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One report described nine patients with cardiogenic but nonischemic pulmonary edema who developed large inverted T waves with marked QT interval prolongation within 24 hours of treatment and stabilization [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/10\">",
"     10",
"    </a>",
"    ]. These repolarization abnormalities resolved within one week and were not associated with any in-hospital mortality.",
"   </p>",
"   <p>",
"    The causes of these ECG changes may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subendocardial ischemia due to increased wall stress, high end-diastolic pressure, or decreased coronary artery flow",
"     </li>",
"     <li>",
"      An acute increase in cardiac sympathetic tone",
"     </li>",
"     <li>",
"      An increase in electrical heterogeneity due to underlying myocardial damage or hypertrophy and exacerbated by ischemia, metabolic changes, or catecholamines.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chest radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic findings in ADHF can range from mild pulmonary vascular redistribution to marked cardiomegaly and extensive bilateral interstitial markings (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53728 graphicRef61783 graphicRef72562 graphicRef75936 \" href=\"UTD.htm?39/43/40634\">",
"     image 1A-D",
"    </a>",
"    ). The presence of bilateral perihilar alveolar edema may give the typical \"butterfly\" appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/11\">",
"     11",
"    </a>",
"    ]. Pleural effusions are often absent given the acute nature of the accumulation of pulmonary edema. A normal chest radiograph does not exclude ADHF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial laboratory data can be obtained but is usually not needed to make the diagnosis or guide initial therapy; treatment should NOT be delayed while waiting for the results of laboratory tests.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An arterial blood specimen or pulse oximetry can quantify the level of hypoxia if oxygen saturation is low. Arterial blood gas analysis is recommended in all patients with severe respiratory distress for information on ventilatory and acid-base status [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A complete blood count may help identify the presence of infection or anemia that may have precipitated the event.",
"     </li>",
"     <li>",
"      Routine chemistries may identify renal dysfunction. This may be due in part to a low output state, a setting in which the blood urea nitrogen (BUN) and serum creatinine concentrations can be used as a marker of cardiac output, or to underlying renal disease, particularly bilateral renal artery stenosis.",
"     </li>",
"     <li>",
"      If ongoing myocardial ischemia is suspected, cardiac enzymes should be measured to evaluate potential myocardial injury. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"       \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28101?source=see_link\">",
"       \"Biomarkers of cardiac injury other than troponins and creatine kinase\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Diagnostic utility of BNP and NT-proBNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) assays can supplement clinical judgment when the cause of a patient's dyspnea is uncertain, particularly among patients with an intermediate probability of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. Results should be interpreted in the context of all available clinical data [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Echocardiography and other imaging modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major society guidelines recommend Doppler echocardiography to aid in the diagnosis and classification of heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Assessment of ventricular function by echocardiography or other method (eg, radionuclide, CMR, CT, or contrast ventriculography) is helpful in characterizing the type (systolic versus diastolic), severity, and potential cause of ventricular dysfunction.",
"   </p>",
"   <p>",
"    When reduced LVEF (&lt;40 percent) is found, the cause of heart failure may be ascribed to systolic dysfunction (with or without other causes such as diastolic dysfunction or valvular disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/4\">",
"     4",
"    </a>",
"    ]. When preserved left ventricular systolic function is found, the cause of heart failure may be diastolic dysfunction, transient systolic dysfunction, other cause of heart failure with preserved ejection fraction (",
"    <a class=\"graphic graphic_table graphicRef54975 \" href=\"UTD.htm?19/7/19580\">",
"     table 1",
"    </a>",
"    ), or diagnostic error (no heart failure with",
"    <span class=\"nowrap\">",
"     symptoms/signs",
"    </span>",
"    due to another cause).",
"   </p>",
"   <p>",
"    Two-dimensional and Doppler echocardiography enables evaluation of ventricular size, global and regional systolic function, diastolic function, valvular disease, and pericardial disease. Echocardiography also enables estimation of right atrial pressure, pulmonary artery pressures and pulmonary capillary wedge pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link&amp;anchor=H21#H21\">",
"     \"Evaluation of the patient with suspected heart failure\", section on 'Echocardiography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28503?source=see_link\">",
"     \"Pathophysiology of cardiogenic pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with STEMI and pulmonary congestion, echocardiography should be performed urgently to estimate LV and RV function and to exclude a mechanical complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=see_link\">",
"     \"Mechanical complications of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Swan-Ganz catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available evidence on flow-directed pulmonary artery (Swan-Ganz) catheters in patients with ADHF does",
"    <strong>",
"     not",
"    </strong>",
"    support their routine use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4743?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of refractory heart failure\", section on 'Hemodynamic monitoring'",
"    </a>",
"    .) Thus, routine use of invasive hemodynamic monitoring in patients with ADHF is NOT recommended by the 2010 HFSA or 2009",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend invasive hemodynamic monitoring in patients who are in respiratory distress or have clinical evidence of hypoperfusion in whom the excess or adequacy of intracardiac filling pressure cannot be determined by clinical assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, invasive monitoring can be useful in carefully selected patients with persistent symptoms despite empiric adjustment of standard therapies and one of the following conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Volume status, perfusion or systemic or pulmonary vascular resistances are uncertain.",
"     </li>",
"     <li>",
"      Systolic pressure remains low, or is associated with symptoms, despite initial therapy.",
"     </li>",
"     <li>",
"      Renal function is worsening with therapy.",
"     </li>",
"     <li>",
"      Parenteral vasoactive agents are required, OR",
"     </li>",
"     <li>",
"      Consideration of advanced device therapy or cardiac transplantation may be required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A pulmonary capillary wedge pressure &ge;18 mmHg favors cardiogenic pulmonary edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=see_link\">",
"     \"Pulmonary artery catheterization: Interpretation of tracings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, it is important to appreciate that pulmonary artery catheterization measurements can be misleading in certain settings. Most important, myocardial ischemia can cause severe but transient left ventricular dysfunction. If the wedge pressure is first measured after the ischemia has resolved (and if left ventricular function has improved), a relatively normal value may be obtained, leading to the erroneous conclusion that the respiratory distress was caused by noncardiogenic mechanisms.",
"   </p>",
"   <p>",
"    On the other hand, an elevated wedge pressure does not exclude the possibility of noncardiogenic pulmonary edema. It is estimated that as many as 20 percent of patients with pulmonary edema due to acute respiratory distress syndrome (ARDS) have concomitant left ventricular dysfunction. The contribution of ARDS to the pulmonary edema requires monitoring the wedge pressure response to treatment. Noncardiogenic factors are probable if the pulmonary infiltrates and hypoxemia do not improve appreciably within 24 to 48 hours after normalization of the wedge pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=see_link\">",
"     \"Noncardiogenic pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with adequate acoustic windows, echocardiography may provide a noninvasive means of estimating filling pressures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7897?source=see_link&amp;anchor=H14#H14\">",
"     \"Tissue Doppler echocardiography\", section on 'Estimation of LV filling pressures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent or early coronary angiography and intervention is indicated in patients with ADHF and an acute coronary syndrome. As recommended in the 2009 focused update of the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    HF guidelines, urgent cardiac catheterization and revascularization is reasonable when it is likely to prolong meaningful survival in patients with acute HF and known or suspected acute myocardial ischemia due to occlusive coronary disease, especially when there are signs and symptoms of systemic hypoperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33446?source=see_link\">",
"     \"Treatment of acute decompensated heart failure in acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since ADHF frequently presents with the sudden onset of respiratory distress that may or may not be associated with chest discomfort or a previous history of heart disease, other medical conditions must be excluded:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary embolism &mdash; The sudden onset of dyspnea, pleuritic chest pain, and cough may reflect a pulmonary embolism (PE). Establishing the diagnosis may depend upon the characteristics of the ECG and the difference in appearance of typical chest x-ray findings in the two conditions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In addition to being part of the differential diagnosis, venous thromboembolism is more common in patients with heart failure and, in patients with ADHF, is associated with a worse prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7544/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=see_link\">",
"       \"Indications for antithrombotic therapy in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumonia &mdash; Pneumonia can present with acute shortness of breath, hypoxemia, and an inconclusive pulmonary examination. Chest x-ray findings may be similar to HF in cases of bibasilar pneumonia or unilateral pulmonary edema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"       \"Diagnostic approach to community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Asthma &mdash; Reactive airways disease can cause acute shortness of breath, cough, and fatigue. In addition, patients with ADHF may present with wheezing that can simulate asthma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"       \"Diagnosis of asthma in adolescents and adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    Basics topics (see",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?11/4/11331?source=see_link\">",
"     \"Patient information: When your lungs fill with fluid (The Basics)\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92291288\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute decompensated heart failure (ADHF) is characterized by the development of acute dyspnea associated with elevated left sided filling pressures with or without pulmonary edema. Heart failure may be new or an exacerbation of chronic disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical signs and symptoms'",
"      </a>",
"      above.) Initial assessment should include a brief, focused history and physical examination to evaluate signs and symptoms of HF as well as potential contributing factors and comorbidities. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Precipitating factors for ADHF include adherence and process of care issues, cardiac and noncardiac disorders. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Identification of precipitating factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Flash pulmonary edema is a dramatic form of ADHF in which acute increases in left ventricular diastolic pressure cause rapid fluid accumulation in the pulmonary interstitium and alveolar spaces. (See",
"      <a class=\"local\" href=\"#H22643398\">",
"       'Flash pulmonary edema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute coronary syndrome precipitating ADHF should be promptly identified by electrocardiogram and cardiac troponin testing and treated as appropriate for the condition and prognosis of the patient with consideration of coronary angiography. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Electrocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) assays can supplement clinical judgment when the cause of a patient's dyspnea is uncertain, particularly among patients with an intermediate probability of HF. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnostic utility of BNP and NT-proBNP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine use of invasive hemodynamic monitoring in patients with ADHF is",
"      <strong>",
"       not",
"      </strong>",
"      recommended. However, invasive hemodynamic monitoring is indicated in patients who are in respiratory distress or have clinical evidence of hypoperfusion in whom clinical assessment cannot adequately determine intracardiac filling pressures. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Swan-Ganz catheter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urgent or early coronary angiography and intervention is indicated in patients with ADHF and an acute coronary syndrome. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Coronary angiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of ADHF includes other causes of acute respiratory distress such as pulmonary embolism, pneumonia, and asthma. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7544/abstract/1\">",
"      Ware LB, Matthay MA. Clinical practice. Acute pulmonary edema. N Engl J Med 2005; 353:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7544/abstract/2\">",
"      Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7544/abstract/3\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7544/abstract/4\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7544/abstract/5\">",
"      Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006; 22:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7544/abstract/6\">",
"      Jorge S, Becquemin MH, Delerme S, et al. Cardiac asthma in elderly patients: incidence, clinical presentation and outcome. BMC Cardiovasc Disord 2007; 7:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7544/abstract/7\">",
"      Flaherty JD, Bax JJ, De Luca L, et al. Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. J Am Coll Cardiol 2009; 53:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7544/abstract/8\">",
"      Pickering TG, Herman L, Devereux RB, et al. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: treatment by angioplasty or surgical revascularisation. Lancet 1988; 2:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7544/abstract/9\">",
"      Messerli FH, Bangalore S, Makani H, et al. Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering syndrome. Eur Heart J 2011; 32:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7544/abstract/10\">",
"      Littmann L. Large T wave inversion and QT prolongation associated with pulmonary edema: a report of nine cases. J Am Coll Cardiol 1999; 34:1106.",
"     </a>",
"    </li>",
"    <li>",
"     Neville, RA. Squire's Fundamentals of Radiology, Harvard University Press, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7544/abstract/12\">",
"      Collins SP, Lindsell CJ, Storrow AB, et al. Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. Ann Emerg Med 2006; 47:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7544/abstract/13\">",
"      Weintraub NL, Collins SP, Pang PS, et al. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation 2010; 122:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7544/abstract/14\">",
"      Darze ES, Latado AL, Guimar&atilde;es AG, et al. Acute pulmonary embolism is an independent predictor of adverse events in severe decompensated heart failure patients. Chest 2007; 131:1838.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3497 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-C9F66847B9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_23_7544=[""].join("\n");
var outline_f7_23_7544=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H92291288\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Identification of precipitating factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22643398\">",
"      - Flash pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chest radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Diagnostic utility of BNP and NT-proBNP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Echocardiography and other imaging modalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Swan-Ganz catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92291288\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3497\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3497|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/54/3941\" title=\"diagnostic image 1A\">",
"      Interstitial pulmonary edema PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/32/12805\" title=\"diagnostic image 1B\">",
"      Heart failure PA I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/37/29267\" title=\"diagnostic image 1C\">",
"      Heart failure PA II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/6/10340\" title=\"diagnostic image 1D\">",
"      Pulmonary edema II PA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3497|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/7/19580\" title=\"table 1\">",
"      Differential diagnosis of HF-PEF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3497|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?39/33/40471\" title=\"waveform 1\">",
"      ECG in flash pulmonary edema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=related_link\">",
"      Acute aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28101?source=related_link\">",
"      Biomarkers of cardiac injury other than troponins and creatine kinase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=related_link\">",
"      Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=related_link\">",
"      Drugs that should be avoided or used with caution in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=related_link\">",
"      Electrocardiographic diagnosis of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=related_link\">",
"      Epidemiology and causes of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4743?source=related_link\">",
"      Management of refractory heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25271?source=related_link\">",
"      Neurogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28503?source=related_link\">",
"      Pathophysiology of cardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=related_link\">",
"      Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/4/11331?source=related_link\">",
"      Patient information: When your lungs fill with fluid (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=related_link\">",
"      Pulmonary artery catheterization: Interpretation of tracings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=related_link\">",
"      Stress-induced (takotsubo) cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7897?source=related_link\">",
"      Tissue Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33446?source=related_link\">",
"      Treatment of acute decompensated heart failure in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29031?source=related_link\">",
"      Treatment of hypertension in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=related_link\">",
"      Treatment of specific hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_23_7545="Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis";
var content_f7_23_7545=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/23/7545/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7545/contributors\">",
"     Martha Sajatovic, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7545/contributors\">",
"     Peijun Chen, MD, MPH, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/23/7545/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7545/contributors\">",
"     Paul Keck, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7545/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/23/7545/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7545/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/23/7545/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7213941\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features and treatment of older bipolar patients differ from those of younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/1\">",
"     1",
"    </a>",
"    ]. Up to 25 percent of all bipolar patients are elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/2\">",
"     2",
"    </a>",
"    ], and the absolute number of geriatric bipolar patients is expected to increase as the world&rsquo;s population ages over the next several decades [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the epidemiology, pathogenesis, clinical features, assessment, diagnosis, and differential diagnosis of geriatric bipolar disorder. The treatment and prognosis of geriatric bipolar disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16330?source=see_link\">",
"     \"Geriatric bipolar disorder: Acute treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22601?source=see_link\">",
"     \"Geriatric bipolar disorder: Maintenance treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260045733\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The minimum age used to define geriatric bipolar disorder is generally 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/5\">",
"     5",
"    </a>",
"    ]. However, some authorities use an age cut-off of 50, 55, or 65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/6\">",
"     6",
"    </a>",
"    ]. Geriatric bipolar disorder includes both aging patients whose mood disorder presented earlier in life, and patients whose mood disorder presents for the first time in later life [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/1,7\">",
"     1,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7213948\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of geriatric bipolar disorder varies depending upon the setting and study sample. The estimated one-year prevalence of bipolar disorder in the United States general population aged 65 years or older is 0.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/8\">",
"     8",
"    </a>",
"    ]; the estimated lifetime rate for individuals aged 60 years or older is 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/9\">",
"     9",
"    </a>",
"    ]. The prevalence of geriatric bipolar disorder is higher in clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nursing home residents &ndash; 3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Psychiatric outpatients &ndash; 6 to 7 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/6,11\">",
"       6,11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Psychiatric inpatients &ndash; 7 to 10 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      General hospital emergency department &ndash; 17 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bipolar patients &ndash; 7 to 25 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/2,12-14\">",
"       2,12-14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among geriatric bipolar patients treated in clinical settings, approximately 70 to 95 percent represent cases with onset prior to age 50 years that has persisted into later life [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/13,15\">",
"     13,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Geriatric bipolar patients are predominantly female; a review of 17 studies found that approximately 69 percent of late-life bipolar patients were women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/6\">",
"     6",
"    </a>",
"    ]. By contrast, a cross-national epidemiologic study of mostly younger bipolar adults found that the ratio of females to males was approximately 1:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/16\">",
"     16",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7214004\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not known what causes bipolar disorder. However, the etiology of late-onset geriatric bipolar disorder (age 50 years or older) may possibly differ from earlier-onset bipolar disorder that has persisted into later life [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/17\">",
"     17",
"    </a>",
"    ]. This is suggested by observations that cerebrovascular pathology occurs in more late-onset geriatric bipolar patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/6\">",
"     6",
"    </a>",
"    ]. As an example, one neuroimaging study detected cerebrovascular lesions (with no associated focal neurologic symptoms) in significantly more late-onset geriatric bipolar patients (N = 20) than age-matched, earlier-onset patients (N = 20) (65 versus 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mood episodes that occur in geriatric bipolar patients may possibly be due in part to negative life events such as marital discord as well as changes in family role, residence, employment, and finances [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. One study found that older bipolar patients had more than twice as many stressful life events compared with age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7214018\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is characterized by episodes of major depression (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"     table 1",
"    </a>",
"    ), mania (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"UTD.htm?3/53/3932\">",
"     table 2",
"    </a>",
"    ), and hypomania (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"UTD.htm?22/39/23164\">",
"     table 3",
"    </a>",
"    ), as well as mixed episodes (major depression concurrent with mania) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/21\">",
"     21",
"    </a>",
"    ]. However, the clinical features of bipolar disorder are different for older and younger patients in that [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/1,22-25\">",
"     1,22-25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cognitive impairment is more common and severe in geriatric patients",
"     </li>",
"     <li>",
"      Comorbid general medical illnesses are more common in older patients",
"     </li>",
"     <li>",
"      Excessive sexual interest and behavior during manic or hypomanic episodes appear to be less common in older patients",
"     </li>",
"     <li>",
"      Comorbid anxiety and substance use disorders are less common in geriatric patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical features of late-onset geriatric bipolar disorder (age 50 years or older) and earlier-onset bipolar disorder that has persisted into later life appear to be similar [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/13,26\">",
"     13,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1522530\">",
"    <span class=\"h2\">",
"     Cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive deficits occur in approximately 40 to 50 percent of euthymic, geriatric bipolar patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Comparisons with age-matched healthy controls show that late-life bipolar patients have deficits in [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/27,29-31\">",
"     27,29-31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Executive functions",
"     </li>",
"     <li>",
"      Verbal memory",
"     </li>",
"     <li>",
"      Psychomotor speed",
"     </li>",
"     <li>",
"      Global cognitive functioning",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These deficits are similar to the types of cognitive deficits that are observed in euthymic, younger adult bipolar patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. However, neuropsychologic impairment occurs more frequently and is more severe in geriatric bipolar patients than younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with geriatric bipolar disorder may develop dementia at a higher than expected rate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. A study of 4668 veterans with geriatric bipolar disorder found that dementia was present in 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/36\">",
"     36",
"    </a>",
"    ]. A review of five studies found that as many as 25 to 30 percent of inpatients with late-life bipolar disorder were also demented [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21815651\">",
"    <span class=\"h2\">",
"     Comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comorbidity is common in late-life bipolar disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/6,17\">",
"     6,17",
"    </a>",
"    ]. A study of approximately 300 geriatric patients hospitalized for bipolar disorder found that the median number of comorbid disorders was seven [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/37\">",
"     37",
"    </a>",
"    ]. Much of the comorbidity is accounted for by general medical illnesses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260423079\">",
"    <span class=\"h3\">",
"     General medical disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;General medical conditions are significantly more common in geriatric bipolar patients than younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/1,38\">",
"     1,38",
"    </a>",
"    ]. One study of 54 late-life bipolar patients found that morbidity affected a mean average of six organ systems [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/39\">",
"     39",
"    </a>",
"    ]. The most common illnesses are [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypertension &ndash; 80 percent of geriatric bipolar patients",
"     </li>",
"     <li>",
"      Hyperlipidemia &ndash; 75 percent",
"     </li>",
"     <li>",
"      Diabetes &ndash; 32 percent",
"     </li>",
"     <li>",
"      Hypothyroidism &ndash; 22 percent",
"     </li>",
"     <li>",
"      Coronary heart disease &ndash; 19 percent",
"     </li>",
"     <li>",
"      Asthma &ndash; 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These general medical illnesses are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=see_link\">",
"     \"Overview of hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31222?source=see_link\">",
"     \"Measurement of serum lipids and lipoproteins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link\">",
"     \"Screening for coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5818?source=see_link\">",
"     \"Diagnosis and management of asthma in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21815569\">",
"    <span class=\"h3\">",
"     Psychiatric disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substance use disorders and anxiety disorders are the two most common psychiatric comorbidities in geriatric bipolar disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/6,11,22\">",
"     6,11,22",
"    </a>",
"    ]. However, the prevalence of substance use and anxiety disorders is significantly less in geriatric bipolar patients than younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/22,41\">",
"     22,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87684659\">",
"    <span class=\"h4\">",
"     Substance use disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substance use disorders occur in approximately 10 to 40 percent of geriatric bipolar patients, depending upon the study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/11,22,36,41\">",
"     11,22,36,41",
"    </a>",
"    ]. By contrast, comorbid substance use disorders occur in approximately 60 percent or more of younger bipolar patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/42\">",
"     42",
"    </a>",
"    ]. Substance use disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18244130\">",
"    <span class=\"h4\">",
"     Anxiety disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety disorders occur in about 10 percent of patients with geriatric bipolar disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 16,330 veterans with late-life bipolar disorder found that 10 percent had one or more anxiety disorders, including [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/36\">",
"       36",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Generalized anxiety disorder",
"     </li>",
"     <li>",
"      Panic disorder with or without agoraphobia",
"     </li>",
"     <li>",
"      Social anxiety disorder",
"     </li>",
"     <li>",
"      Specific phobia",
"     </li>",
"     <li>",
"      Obsessive compulsive disorder",
"     </li>",
"     <li>",
"      Anxiety disorder not otherwise specified",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A community survey found that in 84 geriatric bipolar patients, panic disorder occurred in 12 percent and generalized anxiety disorder in 10 percent, which was significantly greater than the prevalence in 8121 elderly controls [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These anxiety disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44744?source=see_link\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22921?source=see_link\">",
"     \"Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36564?source=see_link\">",
"     \"Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1522610\">",
"    <span class=\"h1\">",
"     ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial clinical evaluation of elderly patients with a possible diagnosis of bipolar disorder includes a psychiatric history and mental status examination, with emphasis upon depressive (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"     table 1",
"    </a>",
"    ), manic (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"UTD.htm?3/53/3932\">",
"     table 2",
"    </a>",
"    ), and hypomanic symptoms (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"UTD.htm?22/39/23164\">",
"     table 3",
"    </a>",
"    ), as well as symptoms of substance abuse disorders and anxiety disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/21,43,44\">",
"     21,43,44",
"    </a>",
"    ]. Patients presenting with major depression may not recall prior episodes of mania or hypomania, especially if these last occurred several years or decades in the past, were marked by irritability rather than euphoria, or consisted of post-partum mood states. Interviewing family members can help elicit a past history of mania or hypomania.",
"   </p>",
"   <p>",
"    In addition, the mental status examination should address cognition. We often include the Mini-Mental State Examination, which is a brief test administered by the clinician that evaluates orientation, recall, attention, calculation, language manipulation, and constructional praxis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/45\">",
"     45",
"    </a>",
"    ]. Use of the Mini-Mental State Examination is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of cognitive impairment and dementia\", section on 'Mini-Mental State Examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician should also obtain a general medical history and physical examination, as well as laboratory tests and imaging studies that are guided by the history and examination [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/43,44,46\">",
"     43,44,46",
"    </a>",
"    ]. The medical work-up should emphasize general medical disorders commonly observed in geriatric bipolar patients, which are discussed separately. (See",
"    <a class=\"local\" href=\"#H260423079\">",
"     'General medical disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The initial evaluation of elderly patients with a possible diagnosis of bipolar disorder often occurs in a medical or psychiatric emergency department when the patient presents with reckless behavior, suicidal ideation or behavior, psychosis, functional decline (eg, impaired activities of daily living and social isolation), or exacerbation of a general medical illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1522655\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Self-report screening instruments can help make the diagnosis and save interviewer time, but are more likely to yield false positives than clinician-administered instruments. No screening instruments have been specifically developed for geriatric bipolar disorder. However, self-report screening instruments for bipolar disorder that have been evaluated in mixed-age populations and are easy to use include the:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mood Disorder Questionnaire &ndash; This 15-item instrument screens for episodes of mania and hypomania (",
"      <a class=\"graphic graphic_table graphicRef53409 \" href=\"UTD.htm?19/63/20477\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/47\">",
"       47",
"      </a>",
"      ]. The psychometric properties are good, including a sensitivity of 0.63 to 0.76 and a specificity of 0.85 to 0.90 in psychiatric outpatient clinics [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/48\">",
"       48",
"      </a>",
"      ], and a sensitivity of 0.58 and a specificity of 0.93 in a family medicine clinic [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/49\">",
"       49",
"      </a>",
"      ]. The Mood Disorder Questionnaire does not generate a diagnosis of mania or hypomania; thus, patients who screen positive require a clinical interview to make the diagnosis.",
"     </li>",
"     <li>",
"      Patient Health Questionnaire - 9 Item (PHQ-9) &ndash; This 9-item instrument screens for episodes of major depression, provides a diagnosis, and has good psychometric properties (",
"      <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"       table 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/50\">",
"       50",
"      </a>",
"      ]. The PHQ-9 is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=see_link&amp;anchor=H100014092#H100014092\">",
"       \"Using scales to monitor symptoms and treatment of depression (measurement based care)\", section on 'Patient Health Questionnaire - Nine Item'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1522594\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three subtypes of bipolar disorder that can be diagnosed, depending upon the mood symptoms and episodes that have occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bipolar I",
"     </li>",
"     <li>",
"      Bipolar II",
"     </li>",
"     <li>",
"      Bipolar disorder not otherwise specified",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic criteria for each subtype of bipolar disorder are identical for geriatric and younger patients. Diagnosis of bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7214025\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;New-onset manic symptoms in geriatric patients may be due to a general medical condition rather than bipolar disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In addition, the differential diagnosis of bipolar disorder includes schizophrenia, schizoaffective disorder, unipolar major depression, and substance use disorder, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link&amp;anchor=H14#H14\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99600145\">",
"    <span class=\"h2\">",
"     General medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manic or major depressive episodes that are due to the direct physiologic effects of a general medical condition are distinguished from bipolar disorder and instead classified as a &ldquo;mood disorder due to a general medical condition&rdquo; in the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/21\">",
"     21",
"    </a>",
"    ]. The term &ldquo;organic bipolar affective disorder&rdquo; is used in the World Health Organization's International Classification of Diseases-10th Revision (ICD-10) for mood episodes secondary to medical conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The assessment (general medical history, physical examination, laboratory tests, and imaging studies) is critical for determining whether a general medical condition is present and etiologically related to the patient&rsquo;s mood episode. Among the many potential etiologies for geriatric mania secondary to a general medical condition, the most common include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7545/abstract/7,51,54,55\">",
"     7,51,54,55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple sclerosis &ndash; Multiple sclerosis is characterized by episodes of central nervous system dysfunction that commonly include sensory symptoms (eg, paresthesias, pain, or optic neuritis) and motor symptoms (eg, paraparesis). The clinical findings are augmented with neuroimaging and laboratory studies to diagnose the disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link\">",
"       \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stroke &ndash; Ischemia or hemorrhage results in acute neurologic injury and can cause focal loss of brain function. Strokes in the right orbital frontal lobe, temporal lobe, basal ganglia, or thalamus have been associated with mania. Stroke is diagnosed based upon the results of the history, neurologic exam, and neuroimaging studies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link\">",
"       \"Overview of the evaluation of stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brain tumors &ndash; Brain tumors can present with generalized symptoms (eg, headache, seizures, or nausea) or focal neurologic symptoms (eg, weakness or sensory loss). Neuroradiologic imaging is the major diagnostic modality in the evaluation of brain tumors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"       \"Clinical presentation and diagnosis of brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mild traumatic brain injury due to falls &ndash; Concussion is characterized by confusion and amnesia, often without preceding loss of consciousness. Assessment focuses upon cognition; neuroimaging is usually normal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link\">",
"       \"Concussion and mild traumatic brain injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic infection with the human immunodeficiency virus (HIV) &ndash; Patients infected with HIV can present with an ill-defined febrile illness or aseptic meningitis in the context of high-risk sexual behavior or injection drug abuse. Rash, mucocutaneous ulcers, and lymphadenopathy may be found on physical examination, and serologic testing is positive for HIV antibodies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=see_link\">",
"       \"Acute and early HIV infection: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperthyroidism &ndash; Hyperthyroidism characteristically includes palpitations, heat intolerance, increased perspiration, dyspnea on exertion, and weight loss despite a normal appetite. Physical examination is notable for tachycardia, lid retraction and lid lag, tremor, and enlarged thyroid. Low serum thyrotropin (TSH) and high free T4 and T3 concentrations establish the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"       \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Episodes of major depression may be secondary to general medical conditions (",
"    <a class=\"graphic graphic_table graphicRef52373 \" href=\"UTD.htm?0/13/220\">",
"     table 6",
"    </a>",
"    ); this is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations and diagnosis of depression\", section on 'Medical comorbidity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medication history should be evaluated among elderly patients with new-onset mania or major depression, especially new treatments initiated by other clinicians (eg, steroids for arthritis, asthma, or inflammatory bowel disease; or dopaminergic drugs for Parkinson disease or restlessness legs syndrome) and complementary and alternative medications initiated by the patient (eg, St John&rsquo;s wort for depression).",
"   </p>",
"   <p>",
"    Management of mood episodes secondary to a general medical condition includes concurrent treatment of the mood symptoms and general medical condition. Acute treatment of geriatric mood episodes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16330?source=see_link&amp;anchor=H13749322#H13749322\">",
"     \"Geriatric bipolar disorder: Acute treatment\", section on 'Manic, hypomanic, and mixed episodes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16330?source=see_link&amp;anchor=H13749357#H13749357\">",
"     \"Geriatric bipolar disorder: Acute treatment\", section on 'Bipolar major depression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/5/4178?source=see_link\">",
"       \"Patient information: Bipolar disorder (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=see_link\">",
"       \"Patient information: Bipolar disorder (manic depression) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These educational materials can be used as part of psychoeducational psychotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=see_link&amp;anchor=H21#H21\">",
"     \"Bipolar disorder in adults: Maintenance treatment\", section on 'Psychoeducation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled \"Bipolar Disorder,\" which is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml\">",
"     file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml",
"    </a>",
"    or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.",
"   </p>",
"   <p>",
"    More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).",
"   </p>",
"   <p>",
"    The Depression and Bipolar Support Alliance (",
"    <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"     file://www.dbsalliance.org",
"    </a>",
"    or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.",
"   </p>",
"   <p>",
"    The National Alliance on Mental Illness (",
"    <a class=\"external\" href=\"file://www.nami.org/\">",
"     file://www.nami.org",
"    </a>",
"    or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7214137\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The minimum age used to define geriatric bipolar disorder is generally 60 years. (See",
"      <a class=\"local\" href=\"#H260045733\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The estimated lifetime prevalence of bipolar disorder in the United States general population aged 60 years or older is 1 percent. Geriatric patients represent between 7 and 25 percent of all bipolar patients. (See",
"      <a class=\"local\" href=\"#H7213948\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of geriatric bipolar disorder is not known. However, the etiology of late-onset geriatric bipolar disorder (age 50 years or older) may possibly differ from earlier-onset bipolar disorder that has persisted into later life. (See",
"      <a class=\"local\" href=\"#H7214004\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bipolar disorder is characterized by episodes of major depression (",
"      <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"       table 1",
"      </a>",
"      ), mania (",
"      <a class=\"graphic graphic_table graphicRef81976 \" href=\"UTD.htm?3/53/3932\">",
"       table 2",
"      </a>",
"      ), hypomania (",
"      <a class=\"graphic graphic_table graphicRef70757 \" href=\"UTD.htm?22/39/23164\">",
"       table 3",
"      </a>",
"      ), and major depression concurrent with mania or hypomania. The clinical features of older and younger bipolar patients differ in that cognitive impairment is more common and severe in geriatric patients. In addition, general medical comorbidity occurs more often in geriatric bipolar patients than younger patients. By contrast, comorbid anxiety and substance use disorders appear to be less common in geriatric patients. (See",
"      <a class=\"local\" href=\"#H7214018\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The assessment for geriatric bipolar disorder includes a psychiatric history and mental status examination, with emphasis upon depressive and manic symptoms. The work-up also includes a general medical history, physical examination, and focused laboratory tests and imaging studies that assess for general medical disorders such as hypertension, hyperlipidemia, diabetes, hypothyroidism, coronary heart disease, and asthma . (See",
"      <a class=\"local\" href=\"#H1522610\">",
"       'Assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H260423079\">",
"       'General medical disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Self-report screening instruments that can save interviewer time and have been evaluated in mixed-age bipolar populations include the Mood Disorder Questionnaire (",
"      <a class=\"graphic graphic_table graphicRef53409 \" href=\"UTD.htm?19/63/20477\">",
"       table 4",
"      </a>",
"      ), which screens for mania and hypomania, and the Patient Health Questionnaire - 9 Item (PHQ-9) (",
"      <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"       table 5",
"      </a>",
"      ), which screens for and diagnoses major depression. (See",
"      <a class=\"local\" href=\"#H1522655\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are three subtypes of bipolar disorder that can be diagnosed in elderly patients: bipolar I disorder, bipolar II disorder, and bipolar disorder not otherwise specified. (See",
"      <a class=\"local\" href=\"#H1522594\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The differential diagnosis of bipolar disorder includes schizophrenia, schizoaffective disorder, delusional disorder, unipolar major depression, and substance use disorders. In addition, mood episodes may be secondary to a general medical condition (",
"      <a class=\"graphic graphic_table graphicRef52373 \" href=\"UTD.htm?0/13/220\">",
"       table 6",
"      </a>",
"      ), including multiple sclerosis, stroke, brain tumor, concussion, infection with the human immunodeficiency virus (HIV), and hyperthyroidism. (See",
"      <a class=\"local\" href=\"#H7214025\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/1\">",
"      Sajatovic M, Chen P. Geriatric bipolar disorder. Psychiatr Clin North Am 2011; 34:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/2\">",
"      Sajatovic M, Blow FC, Ignacio RV, Kales HC. Age-related modifiers of clinical presentation and health service use among veterans with bipolar disorder. Psychiatr Serv 2004; 55:1014.",
"     </a>",
"    </li>",
"    <li>",
"     United Nations, Department of Economic and Social Affairs, Population Division, Population Estimates and Projections Section. file://esa.un.org/unpd/wpp/index.htm (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/4\">",
"      Jeste DV, Alexopoulos GS, Bartels SJ, et al. Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decades. Arch Gen Psychiatry 1999; 56:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/5\">",
"      Young RC, Schulberg HC, Gildengers AG, et al. Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BD. Bipolar Disord 2010; 12:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/6\">",
"      Depp CA, Jeste DV. Bipolar disorder in older adults: a critical review. Bipolar Disord 2004; 6:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/7\">",
"      Prabhakar D, Balon R. Late-onset bipolar disorder: a case for careful appraisal. Psychiatry (Edgmont) 2010; 7:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/8\">",
"      Weissman MM, Leaf PJ, Tischler GL, et al. Affective disorders in five United States communities. Psychol Med 1988; 18:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/9\">",
"      Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/10\">",
"      Tariot PN, Podgorski CA, Blazina L, Leibovici A. Mental disorders in the nursing home: another perspective. Am J Psychiatry 1993; 150:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/11\">",
"      Depp CA, Lindamer LA, Folsom DP, et al. Differences in clinical features and mental health service use in bipolar disorder across the lifespan. Am J Geriatr Psychiatry 2005; 13:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/12\">",
"      Al Jurdi RK, Marangell LB, Petersen NJ, et al. Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a \"recovered\" status in the systematic treatment enhancement program for bipolar disorder. Am J Geriatr Psychiatry 2008; 16:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/13\">",
"      Oostervink F, Boomsma MM, Nolen WA, EMBLEM Advisory Board. Bipolar disorder in the elderly; different effects of age and of age of onset. J Affect Disord 2009; 116:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/14\">",
"      Goetz I, Tohen M, Reed C, et al. Functional impairment in patients with mania: baseline results of the EMBLEM study. Bipolar Disord 2007; 9:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/15\">",
"      Sajatovic M, Kales HC. Diagnosis and management of bipolar disorder with comorbid anxiety in the elderly. J Clin Psychiatry 2006; 67 Suppl 1:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/16\">",
"      Seedat S, Scott KM, Angermeyer MC, et al. Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. Arch Gen Psychiatry 2009; 66:785.",
"     </a>",
"    </li>",
"    <li>",
"     Sajatovic M, Kessing LV. Bipolar disorder in the elderly. In: Bipolar Disorder: Clinical and Neurobiological Foundations, Yatham LN, Maj M.  (Eds), Wiley-Blackwell, West Sussex 2010. p.488.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/18\">",
"      Fujikawa T, Yamawaki S, Touhouda Y. Silent cerebral infarctions in patients with late-onset mania. Stroke 1995; 26:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/19\">",
"      Yassa R, Nair V, Nastase C, et al. Prevalence of bipolar disorder in a psychogeriatric population. J Affect Disord 1988; 14:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/20\">",
"      Beyer JL, Kuchibhatla M, Cassidy F, Krishnan KR. Stressful life events in older bipolar patients. Int J Geriatr Psychiatry 2008; 23:1271.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/22\">",
"      Goldstein BI, Herrmann N, Shulman KI. Comorbidity in bipolar disorder among the elderly: results from an epidemiological community sample. Am J Psychiatry 2006; 163:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/23\">",
"      Burt T, Prudic J, Peyser S, et al. Learning and memory in bipolar and unipolar major depression: effects of aging. Neuropsychiatry Neuropsychol Behav Neurol 2000; 13:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/24\">",
"      Broadhead J, Jacoby R. Mania in old age: A first prospective study. Int J Geriatr Psychiatry 1990; 5:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/25\">",
"      Young RC, Kiosses D, Heo M, et al. Age and ratings of manic psychopathology. Bipolar Disord 2007; 9:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/26\">",
"      Chu D, Gildengers AG, Houck PR, et al. Does age at onset have clinical significance in older adults with bipolar disorder? Int J Geriatr Psychiatry 2010; 25:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/27\">",
"      Gildengers AG, Butters MA, Seligman K, et al. Cognitive functioning in late-life bipolar disorder. Am J Psychiatry 2004; 161:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/28\">",
"      Tsai SY, Lee HC, Chen CC, Huang YL. Cognitive impairment in later life in patients with early-onset bipolar disorder. Bipolar Disord 2007; 9:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/29\">",
"      Martino DJ, Igoa A, Marengo E, et al. Cognitive and motor features in elderly people with bipolar disorder. J Affect Disord 2008; 105:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/30\">",
"      Gildengers AG, Butters MA, Chisholm D, et al. Cognitive functioning and instrumental activities of daily living in late-life bipolar disorder. Am J Geriatr Psychiatry 2007; 15:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/31\">",
"      Gildengers AG, Chisholm D, Butters MA, et al. Two-year course of cognitive function and instrumental activities of daily living in older adults with bipolar disorder: evidence for neuroprogression? Psychol Med 2013; 43:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/32\">",
"      Robinson LJ, Thompson JM, Gallagher P, et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord 2006; 93:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/33\">",
"      Arts B, Jabben N, Krabbendam L, van Os J. Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives. Psychol Med 2008; 38:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/34\">",
"      Kessing LV, Nilsson FM. Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J Affect Disord 2003; 73:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/35\">",
"      Dhingra U, Rabins PV. Mania in the elderly: a 5-7 year follow-up. J Am Geriatr Soc 1991; 39:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/36\">",
"      Sajatovic M, Blow FC, Ignacio RV. Psychiatric comorbidity in older adults with bipolar disorder. Int J Geriatr Psychiatry 2006; 21:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/37\">",
"      Brown SL. Variations in utilization and cost of inpatient psychiatric services among adults in Maryland. Psychiatr Serv 2001; 52:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/38\">",
"      Kessing LV. Diagnostic subtypes of bipolar disorder in older versus younger adults. Bipolar Disord 2006; 8:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/39\">",
"      Gildengers AG, Whyte EM, Drayer RA, et al. Medical burden in late-life bipolar and major depressive disorders. Am J Geriatr Psychiatry 2008; 16:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/40\">",
"      Kilbourne AM, Post EP, Nossek A, et al. Service delivery in older patients with bipolar disorder: a review and development of a medical care model. Bipolar Disord 2008; 10:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/41\">",
"      Cassidy F, Ahearn EP, Carroll BJ. Substance abuse in bipolar disorder. Bipolar Disord 2001; 3:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/42\">",
"      Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/43\">",
"      Work Group on Psychiatric Evaluation, American Psychiatric Association Steering Committee on Practice Guidlines. Psychiatric evaluation of adults. Second edition. American Psychiatric Association. Am J Psychiatry 2006; 163:3.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Psychiatric Evaluation of Adults, Second Edition, 2006. file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on July 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/45\">",
"      Folstein MF, Folstein SE, McHugh PR. \"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189.",
"     </a>",
"    </li>",
"    <li>",
"     Freudenreich O, Nejad SH, Francis A, Fricchione GL. Psychosis, mania, and catatonia. In: Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL.  (Ed), American Psychiatric Publishing, Washington, DC 2011. p.219.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/47\">",
"      Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000; 157:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/48\">",
"      Hirschfeld RM. The mood disorder questionnaire: its impact on the field [corrected]. Depress Anxiety 2010; 27:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/49\">",
"      Hirschfeld RM, Cass AR, Holt DC, Carlson CA. Screening for bipolar disorder in patients treated for depression in a family medicine clinic. J Am Board Fam Pract 2005; 18:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/50\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/51\">",
"      Van Gerpen MW, Johnson JE, Winstead DK. Mania in the geriatric patient population: a review of the literature. Am J Geriatr Psychiatry 1999; 7:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/52\">",
"      Woolley JD, Wilson MR, Hung E, et al. Frontotemporal dementia and mania. Am J Psychiatry 2007; 164:1811.",
"     </a>",
"    </li>",
"    <li>",
"     The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. file://www.who.int/classifications/icd/en/bluebook.pdf (Accessed on September 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/54\">",
"      Brooks JO 3rd, Hoblyn JC. Secondary mania in older adults. Am J Psychiatry 2005; 162:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7545/abstract/55\">",
"      American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14650 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-335F5A8ACC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_23_7545=[""].join("\n");
var outline_f7_23_7545=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7214137\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7213941\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260045733\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7213948\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7214004\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7214018\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1522530\">",
"      Cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21815651\">",
"      Comorbidity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H260423079\">",
"      - General medical disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21815569\">",
"      - Psychiatric disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H87684659\">",
"      Substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18244130\">",
"      Anxiety disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1522610\">",
"      ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1522655\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1522594\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7214025\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H99600145\">",
"      General medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7214137\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14650\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14650|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17756\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/53/3932\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for mania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/39/23164\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for hypomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/63/20477\" title=\"table 4\">",
"      Mood disorder questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/12/14541\" title=\"table 5\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/13/220\" title=\"table 6\">",
"      Contributors major depression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=related_link\">",
"      Acute and early HIV infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=related_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5818?source=related_link\">",
"      Diagnosis and management of asthma in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16330?source=related_link\">",
"      Geriatric bipolar disorder: Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22601?source=related_link\">",
"      Geriatric bipolar disorder: Maintenance treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31222?source=related_link\">",
"      Measurement of serum lipids and lipoproteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36564?source=related_link\">",
"      Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=related_link\">",
"      Panic disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/5/4178?source=related_link\">",
"      Patient information: Bipolar disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=related_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44744?source=related_link\">",
"      Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22921?source=related_link\">",
"      Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=related_link\">",
"      Using scales to monitor symptoms and treatment of depression (measurement based care)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_23_7546="Lymphomatoid papulosis";
var content_f7_23_7546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lymphomatoid papulosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/23/7546/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7546/contributors\">",
"     Marshall E Kadin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/23/7546/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7546/contributors\">",
"     John A Zic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/23/7546/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/23/7546/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/23/7546/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H18325839\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphomatoid papulosis (LyP) is a recurrent, self-healing papulonodular skin eruption with histologic features of a CD30+ malignant T cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. LyP is part of the group of cutaneous CD30+ lymphoproliferative disorders (LPDs) that includes primary cutaneous anaplastic large cell lymphoma (pcALCL) and borderline CD30",
"    <sup>",
"     +",
"    </sup>",
"    lesions.",
"   </p>",
"   <p>",
"    LyP is characterized by a chronic course, lasting years or decades. Grouped or disseminated papules and nodules develop and spontaneously regress over weeks to months (",
"    <a class=\"graphic graphic_picture graphicRef71441 \" href=\"UTD.htm?13/1/13333\">",
"     picture 2D",
"    </a>",
"    ). Patients with LyP have an excellent prognosis, although they are at increased risk of developing a second cutaneous or nodal lymphoma, such as mycosis fungoides, pcALCL, or Hodgkin lymphoma.",
"   </p>",
"   <p>",
"    This topic will discuss the clinical presentation, diagnosis, and treatment of LyP. Other cutaneous T cell lymphomas are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35126?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T-cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18325846\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphomatoid papulosis (LyP) is a rare disease. It occurs in patients of all ethnic groups with a peak incidence in the fifth decade. However, LyP may occur in children and individuals older than 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In a series of 111 patients, 60 percent&nbsp;of male patients&nbsp;but only 25 percent of female patients were&nbsp;&le;18 years old at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LyP is associated with a lifelong increased risk of malignant lymphoma. In 5 to 20 percent of patients, LyP may be preceded, associated with, or followed by a malignant lymphoma, generally mycosis fungoides (MF), cutaneous or systemic anaplastic large cell lymphoma (ALCL), or Hodgkin lymphoma (HL) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/3,5,7\">",
"     3,5,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7532316\">",
"     'Associated lymphomas'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18325853\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of lymphomatoid papulosis (LyP) is unknown. The hypothesis of a viral etiology has not been confirmed. In several studies, oncogenic or lymphotropic viruses, including Epstein-Barr virus, herpes viruses 6, 7, and 8, and human T-cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    virus were not detected in LyP lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/8-12\">",
"     8-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Overexpression of CD30",
"    </strong>",
"    &mdash; The overexpression of CD30 on the large atypical T cells found in the skin lesions is the hallmark of LyP and primary cutaneous anaplastic large-cell lymphoma (pcALCL). CD30 is a cell surface cytokine receptor belonging to the tumor necrosis factor (TNF) receptor superfamily 8, first identified on the Reed-Sternberg cells in Hodgkin lymphoma. CD30 is expressed on activated T and B cells but not on mature circulating T or B cells. The interaction of CD30 with its membrane-associated glycoprotein ligand (CD30L) activates the NF-&kappa;B signal transduction pathway resulting in either cell proliferation or apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genetic abnormalities underlying the CD30 overexpression in LyP are largely unknown. One study found that two allelic forms of the CD30 promoter microsatellite repressive element, designated 30M377 and 30M362, were associated with the development of LyP and progression to CD30+ lymphomas in LyP patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/14\">",
"     14",
"    </a>",
"    ]. These findings suggest that allele-specific differences in the control of CD30 transcription may have a role in the pathogenesis of CD30+ cutaneous lymphoproliferative disorders.",
"   </p>",
"   <p>",
"    <strong>",
"     Clonality of T cells",
"    </strong>",
"    &mdash; Monoclonal rearrangement of the T cell receptor (",
"    <em>",
"     TCR",
"    </em>",
"    ) genes has been detected in 40 to 100 percent of the LyP skin lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. In patients with LyP and associated lymphoma, identical rearrangements have been identified in LyP lesions and lymphoma cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/19-27\">",
"     19-27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7532316\">",
"     'Associated lymphomas'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several studies indicate that the CD30+ cells are the clonal T cells in LyP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/15,19,20,28,29\">",
"     15,19,20,28,29",
"    </a>",
"    ]. However, it is not known whether the clonal T cells persist in the skin or in the peripheral blood during the remission periods [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an analysis of the",
"    <em>",
"     TCR",
"    </em>",
"    gene rearrangements, multiple skin and blood samples were obtained from patients with LyP at the time of active disease and remission [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/16\">",
"     16",
"    </a>",
"    ]. Overall, clonal T cell populations were detected in 78 percent of the skin samples and in 36 percent of blood samples. The direct comparison of the clonal T cell populations detected in the lesional skin and corresponding blood sample of each patient revealed a different rearrangement pattern in all instances. These findings suggest that T cell clones detected in the peripheral blood of LyP patients are nonneoplastic and represent a reactive response to an unknown antigen.",
"   </p>",
"   <p>",
"    <strong>",
"     Genetic abnormalities",
"    </strong>",
"    &mdash; Genetic abnormalities found in LyP by classic cytogenetic studies include aneuploidy and chromosomal aberrations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/9,30\">",
"     9,30",
"    </a>",
"    ]. The t(2;5)(p23,q35) translocation characteristic of systemic ALCL has not been found in LyP cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/31\">",
"     31",
"    </a>",
"    ]. However, there is immunohistochemical evidence of increased expression in LyP cells of the oncogenic transcription factor gene",
"    <em>",
"     Fra2",
"    </em>",
"    and inhibitor of differentiation gene",
"    <em>",
"     Id2",
"    </em>",
"    , which are located in close proximity to the t(2;5) breakpoint, suggesting a pathogenetic relationship between LyP and systemic ALCL [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Spontaneous regression",
"    </strong>",
"    &mdash; The mechanisms underlying the spontaneous regression of LyP lesions are unknown. The prevailing hypothesis is that the coexpression of CD30 and the death receptor CD95 (Fas) ligands in LyP lesions may be responsible for the self-regression of LyP lesions through enhanced apoptosis of proliferating cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/33\">",
"     33",
"    </a>",
"    ]. This hypothesis is supported by several observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LyP and plaque-stage mycosis fungoides (MF) have a higher",
"      <span class=\"nowrap\">",
"       apoptosis/proliferation",
"      </span>",
"      ratio than more aggressive cutaneous lymphomas such as tumor stage MF, cutaneous T cell lymphomas with tumor masses, or cutaneous B cell lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The large atypical CD30+ cells of LyP have a low expression of the anti-apoptotic Bcl-2 protein [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The pro-apoptotic protein BAX is expressed at higher levels in LyP and CD30+ ALCL than in systemic CD30+ lymphoma which does not undergo spontaneous regression and has an aggressive clinical behavior [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7532316\">",
"    <span class=\"h1\">",
"     ASSOCIATED LYMPHOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with lymphomatoid papulosis (LyP) have an increased risk of developing a cutaneous or nodal lymphoid malignancy, including mycosis fungoides (MF), cutaneous or nodal anaplastic large-cell lymphoma (ALCL), and Hodgkin lymphoma. LyP-associated lymphomas develop in 5 to 20 percent of patients and may occur before, concurrent with, or after the onset of LyP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/3,5,7,23,38\">",
"     3,5,7,23,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A clonal relationship between LyP and the associated lymphomas has been established in most of the cases analyzed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/19-27\">",
"     19-27",
"    </a>",
"    ]. The finding of identical",
"    <em>",
"     TCR",
"    </em>",
"    gene rearrangements in LyP and LyP-associated lymphomas suggests that both disorders arise from a common lymphoid progenitor. However, the molecular mechanisms underlying the progression of LyP to malignant lymphoma are unknown. The progression of LyP to ALCL appears to be mediated by the loss of cell growth regulation induced by inactivating mutations of cell surface receptors for transforming growth factor (TGF) beta [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/28,29,39\">",
"     28,29,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no clinical or histopathologic criteria to predict the progression of LyP to a malignant lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/3\">",
"     3",
"    </a>",
"    ]. Observational studies have identified several potential markers of increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Monoclonal",
"      <em>",
"       TCR",
"      </em>",
"      gene rearrangement",
"     </li>",
"     <li>",
"      Coexistence of different histologic types of LyP in individual patient",
"     </li>",
"     <li>",
"      Fascin expression &nbsp;",
"     </li>",
"     <li>",
"      High blood levels of soluble CD30, CD25, IL-6, and IL-8",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18325874\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8448414\">",
"    <span class=\"h2\">",
"     Histologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histology of LyP varies according to the age of the lesion. Early lesions show a limited perivascular collection of lymphocytes with few inflammatory cells and large atypical cells. As lesions evolve, there is accumulation of dermal lymphocytes admixed with large atypical cells resembling immunoblasts, including bi- and multi-nucleated forms similar to",
"    <span class=\"nowrap\">",
"     Hodgkin/Reed-Sternberg",
"    </span>",
"    cells of Hodgkin lymphoma (HL).",
"   </p>",
"   <p>",
"    A variable number of inflammatory cells, mostly neutrophils and eosinophils are also seen (",
"    <a class=\"graphic graphic_picture graphicRef82763 \" href=\"UTD.htm?36/13/37080\">",
"     picture 1A",
"    </a>",
"    ). Neutrophils are usually found within the lumina of small dermal capillaries and serve as a useful diagnostic marker of LyP. Some degree of neutrophilic infiltration of the overlying epidermis is commonly seen, especially in advanced lesions, and may be associated with initial ulceration. Fully developed LyP lesions typically have a wedge-shaped configuration with a deep lying apex (",
"    <a class=\"graphic graphic_picture graphicRef82764 \" href=\"UTD.htm?30/41/31379\">",
"     picture 1B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are four major histologic types of LyP lesions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Type A",
"      </strong>",
"      &minus; Type A is the most common (about 75 percent of cases) and is characterized by a wedge-shaped infiltrate of scattered or clustered large atypical CD30+ cells, intermingled with numerous inflammatory cells, such as small lymphocytes, neutrophils, eosinophils, and histiocytes (",
"      <a class=\"graphic graphic_picture graphicRef82764 \" href=\"UTD.htm?30/41/31379\">",
"       picture 1B",
"      </a>",
"      ). Type A resembles the polymorphous infiltrates of Hodgkin lymphoma. Mitoses are frequent and may be atypical.",
"     </li>",
"     <li>",
"      <strong>",
"       Type B",
"      </strong>",
"      &minus;",
"      <strong>",
"      </strong>",
"      Type B lesions show a predominant epidermotropic infiltrate of smaller atypical CD30+ or CD30- cells with cerebriform nuclei that histologically resembles mycosis fungoides (MF). Unlike MF, LyP type B infiltrates are associated with papular lesions that regress spontaneously.",
"     </li>",
"     <li>",
"      <strong>",
"       Type C",
"      </strong>",
"      &minus;",
"      <strong>",
"      </strong>",
"      Type C lesions contain large dermal clusters or sheets of large atypical CD30+ cells with relatively few inflammatory cells. These lesions resemble foci of cutaneous anaplastic large cell lymphoma (ALCL) and the distinction from ALCL is largely based on clinical presentation.",
"     </li>",
"     <li>",
"      <strong>",
"       Type D",
"      </strong>",
"      &minus;",
"      <strong>",
"      </strong>",
"      Type D (CD8+ cytotoxic T-cell lymphoma-like) lesions are characterized by a pagetoid infiltrate of epidermotropic small- to medium-sized atypical CD8+ and CD30+ lymphoid cells that resembles primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. However, clinically, the lesions appear and behave as LyP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18325881\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large atypical immunoblast-like cells of lymphomatoid papulosis (LyP) have the phenotype of activated T cells expressing Hodgkin lymphoma-related antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/45\">",
"     45",
"    </a>",
"    ]. In type A and type C LyP, these cells have an aberrant T cell phenotype lacking one or more common T cell antigens (CD3, CD2, CD5, or CD7) and are usually CD4+ and less often CD8+. They express CD30, CD25, HLA-DR and CD71, and occasionally CD15 or CD56. In type B LyP, the atypical cells with cerebriform nuclei have a CD3+, CD4+, CD8- phenotype and variable expression of CD30.",
"   </p>",
"   <p>",
"    Cytotoxic granules (granzyme B, perforin, TIA-1) can be found within the cytoplasm in about 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H610323182\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clonal rearrangement of the",
"    <em>",
"     TCR",
"    </em>",
"    genes is observed in 40 to 100 percent of cases of LyP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Identical rearrangements have been demonstrated in LyP lesions and associated lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/19-27\">",
"     19-27",
"    </a>",
"    ]. The t(2;5)(p23;q35) translocation involving the anaplastic lymphoma kinase (ALK), a marker of systemic ALCL, is not found in LyP or in cutaneous ALCL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533382\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphomatoid papulosis (LyP) manifests as a chronic, recurrent, asymptomatic eruption of papules and nodules that spontaneously regress. Systemic symptoms, including fever, sweats, or weight loss are absent in patients with LyP. Their presence raises the suspicion of an associated systemic lymphoma and warrants further evaluation. (See",
"    <a class=\"local\" href=\"#H18325895\">",
"     'Pretreatment evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The lesions of LyP are grouped or disseminated and usually coexist in different developmental stages (",
"    <a class=\"graphic graphic_picture graphicRef77791 \" href=\"UTD.htm?41/60/42946\">",
"     picture 2E",
"    </a>",
"    ). Early lesions appear as small red papules, which evolve to larger papules or nodules that may develop central hemorrhage, necrosis, and crusting and subsequently disappear in three to eight weeks (",
"    <a class=\"graphic graphic_picture graphicRef74972 graphicRef54022 graphicRef82762 \" href=\"UTD.htm?10/41/10906\">",
"     picture 2A-C",
"    </a>",
"    ). The lesions of LyP are generally smaller than 2 cm; larger lesions are occasionally seen and are clinically indistinguishable from those of primary or secondary anaplastic large cell lymphoma (ALCL) (",
"    <a class=\"graphic graphic_picture graphicRef83092 graphicRef83091 graphicRef83089 \" href=\"UTD.htm?36/49/37658\">",
"     picture 3A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=see_link&amp;anchor=H5619109#H5619109\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\", section on 'Primary cutaneous ALCL'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no preferential site of involvement. Lesions typically occur on the extremities and may involve the hands, face, and genitalia. Mucous membranes (eg, oral or vaginal mucosa), are rarely involved [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Localized or regional forms have been reported in a few patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Follicular and pustular variants have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/53-56\">",
"     53-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evolution of an individual lesion generally occurs over three to eight weeks; larger nodules may take months to heal. As lesions resolve, they may take on a brownish-red color and disappear leaving an area of increased pigmentation or scarring (",
"    <a class=\"graphic graphic_picture graphicRef71441 \" href=\"UTD.htm?13/1/13333\">",
"     picture 2D",
"    </a>",
"    ). Ulcerated and necrotic lesions may leave hypo- or hyperpigmented, depressed, varioliform scars.",
"   </p>",
"   <p>",
"    The duration of the disease is highly variable. Crops of lesions may recur and regress for months, years, or even decades.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7711520\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of lymphomatoid papulosis (LyP) is clinically suspected in a patient presenting with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of a recurrent eruption of papules and nodules that evolve and regress spontaneously in the absence of systemic symptoms.",
"     </li>",
"     <li>",
"      Grouped or disseminated papules and nodules in different stages of evolution, some with central ulceration or eschar (",
"      <a class=\"graphic graphic_picture graphicRef74972 graphicRef54022 graphicRef82762 graphicRef71441 graphicRef77791 \" href=\"UTD.htm?41/2/42026\">",
"       picture 2A-E",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7533382\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A skin biopsy for histopathologic, immunohistochemical, and molecular genetic evaluation is necessary to confirm the diagnosis. The complete excision of two or more inflammatory lesions without signs of necrosis or involution provides the optimal specimens for the pathologist.",
"   </p>",
"   <p>",
"    The definitive diagnosis is based upon the correlation of the clinical appearance and course of the skin lesions with the following histologic, immunophenotypic, and cytogenetic features [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A wedge-shaped infiltrate of large atypical T cells, intermingled with numerous inflammatory cells, including small lymphocytes, neutrophils, eosinophils, and histiocytes (type A LyP) (",
"      <a class=\"graphic graphic_picture graphicRef82763 graphicRef82764 \" href=\"UTD.htm?21/35/22074\">",
"       picture 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8448414\">",
"       'Histologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Expression of CD30 on immunohistochemistry (",
"      <a class=\"graphic graphic_picture graphicRef82764 \" href=\"UTD.htm?30/41/31379\">",
"       picture 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18325881\">",
"       'Immunophenotype'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clonal rearrangement of the",
"      <em>",
"       TCR",
"      </em>",
"      genes (in 40 to 100 percent of cases). (See",
"      <a class=\"local\" href=\"#H610323182\">",
"       'Genetic features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20514972\">",
"    <span class=\"h2\">",
"     Diagnostic pitfalls",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of LyP may be difficult or delayed in some patients for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Histological variability",
"      </strong>",
"      &mdash; The histology of LyP is highly variable. The histologic subtypes of LyP probably represent evolutionary stages of the skin lesions and may be seen in individual patients at presentation or at different times in the course of the disease. (See",
"      <a class=\"local\" href=\"#H8448414\">",
"       'Histologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Histologic overlap",
"      </strong>",
"      &mdash; There is considerable clinical, histologic, and immunophenotypic overlap between LyP and primary cutaneous anaplastic large cell lymphoma (pcALCL). As an example, the finding of scattered CD30+ blast cells in a background of mixed inflammatory infiltrate is highly suggestive of LyP, but may be also seen in pcALCL presenting with ulcerated lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/2\">",
"       2",
"      </a>",
"      ]. Conversely, dermal clusters or sheets of large atypical CD30+ cells with relatively few inflammatory cells are characteristic of pcALCL, but can also be found in patients with clinical presentation and course of LyP. (See",
"      <a class=\"local\" href=\"#H8448437\">",
"       'CD30+ lymphoproliferative diseases'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Mimics of CD30+ lymphoproliferative diseases",
"      </strong>",
"      &mdash; CD30+ lymphoid cells can be seen in a wide range of inflammatory and infectious disorders that may be clinically indistinguishable from LyP. (See",
"      <a class=\"local\" href=\"#H8448445\">",
"       'CD30+ inflammatory and infectious diseases'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18325888\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of lymphomatoid papulosis (LyP) includes other lymphoproliferative diseases expressing CD30 and several inflammatory and reactive disorders that contain CD30+ cells and mimic LyP clinically and histologically [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/47\">",
"     47",
"    </a>",
"    ]. The clinicopathologic characteristics of the main disorders that should be differentiated from LyP are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef75494 \" href=\"UTD.htm?26/40/27276\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8448437\">",
"    <span class=\"h2\">",
"     CD30+ lymphoproliferative diseases",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Primary cutaneous anaplastic large cell lymphoma (ALCL)",
"      </strong>",
"      &minus; Primary cutaneous ALCL usually manifests as a solitary, firm, large, and sometimes ulcerated nodule (",
"      <a class=\"graphic graphic_picture graphicRef83089 \" href=\"UTD.htm?11/27/11704\">",
"       picture 3C",
"      </a>",
"      ). Approximately 20 percent of patients have multifocal disease (",
"      <a class=\"graphic graphic_picture graphicRef83092 graphicRef83091 \" href=\"UTD.htm?42/33/43544\">",
"       picture 3A-B",
"      </a>",
"      ). CD30 is expressed by at least 75 percent of the large atypical T cells and clonal TCR and ALK gene rearrangement is found in 90 percent of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=see_link&amp;anchor=H5619109#H5619109\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\", section on 'Primary cutaneous ALCL'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Secondary skin lesions of systemic ALCL",
"      </strong>",
"      &minus; Most systemic ALCLs carry the t(2;5)(p23;q35) translocation and express the anaplastic lymphoma kinase (ALK), which is absent in LyP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=see_link&amp;anchor=H5619109#H5619109\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\", section on 'Primary cutaneous ALCL'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Transformed mycosis fungoides (MF) and S&eacute;zary syndrome (SS)",
"      </strong>",
"      &minus; About half of transformed MF and SS are CD30+. A previous history of patch or plaque MF or erythroderma clarifies the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4713?source=see_link&amp;anchor=H1118949#H1118949\">",
"       \"Staging and prognosis of mycosis fungoides and S&eacute;zary syndrome\", section on 'Transformation to large cell histology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Adult T-cell leukemia-lymphoma",
"      </strong>",
"      &minus; Adult T-cell leukemia-lymphoma (ATLL) is a peripheral T-cell leukemia&ndash;lymphoma caused by the human retrovirus HTLV-1. Most cases have an acute onset with generalized lymphadenopathy. All patients with ATLL have serologic antibodies to HTLV-1. Cutaneous involvement occurs in about 50 percent of cases. Large blast-like cells can be CD30",
"      <sup>",
"       +",
"      </sup>",
"      but are ALK",
"      <sup>",
"       &minus;",
"      </sup>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hodgkin lymphoma (HL)",
"      </strong>",
"      &minus; Skin involvement is rare in HL and primary cutaneous forms are even rarer (",
"      <a class=\"graphic graphic_picture graphicRef83095 \" href=\"UTD.htm?23/33/24082\">",
"       picture 3D",
"      </a>",
"      ). The Reed-Sternberg cells of HL are CD30+ and CD15+. The latter is rarely expressed in LyP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link\">",
"       \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8448445\">",
"    <span class=\"h2\">",
"     CD30+ inflammatory and infectious diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several inflammatory and reactive disorders may contain a significant number of CD30+ cells and mimic lymphomatoid papulosis clinically or histologically [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/47,58\">",
"     47,58",
"    </a>",
"    ]. These disorders, sometimes referred to as CD30+ pseudolymphomas, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pityriasis lichenoides et varioliformis acuta (PLEVA)",
"      </strong>",
"      &minus; PLEVA is a skin disease of unknown etiology clinically characterized by the eruption of crops of papules that evolve to necrotic lesions and eventually resolve leaving varioliform scars (",
"      <a class=\"graphic graphic_picture graphicRef57911 graphicRef83096 \" href=\"UTD.htm?27/47/28408\">",
"       picture 4A-B",
"      </a>",
"      ). LyP and PLEVA may have overlapping clinical, histopathologic, and molecular features [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/59\">",
"       59",
"      </a>",
"      ]. With few exceptions [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/59\">",
"       59",
"      </a>",
"      ], the lymphocytic infiltrate in PLEVA is predominantly CD8+ with few large atypical CD30+ cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17369?source=see_link\">",
"       \"Pityriasis lichenoides et varioliformis acuta (PLEVA)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Reactions to arthropod",
"       <span class=\"nowrap\">",
"        bites/nodular",
"       </span>",
"       scabies",
"      </strong>",
"      &minus; Chronic reactions to insect bites and nodular scabies may simulate LyP clinically and histologically (",
"      <a class=\"graphic graphic_picture graphicRef60849 graphicRef75169 graphicRef83093 \" href=\"UTD.htm?14/16/14602\">",
"       picture 5A-C",
"      </a>",
"      ). The dermis contains a dense inflammatory infiltrate of lymphoid cells and histiocytes, with an admixture of eosinophils and plasma cells and atypical mononuclear cells with hyperchromatic nuclei. A history of exposure and the presence of symptoms (eg, intense pruritus) may help in differentiating arthropod bites from LyP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=see_link&amp;anchor=H7#H7\">",
"       \"Scabies\", section on 'Typical infestation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lymphomatoid drug eruption",
"      </strong>",
"      &minus; A lymphomatoid eruption is a rare type of drug reaction clinically characterized by indurated papules or plaques (",
"      <a class=\"graphic graphic_picture graphicRef83094 \" href=\"UTD.htm?37/26/38306\">",
"       picture 6",
"      </a>",
"      ). Cases associated with the presence of large atypical CD30+ T cells on histologic examination have been reported following the administration of antibiotics, antiepileptics, or biologics [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/58,60-63\">",
"       58,60-63",
"      </a>",
"      ]. The temporal relationship between the drug administration and skin eruptions and the disappearance of the rash after the drug suspension clarifies the diagnosis. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Viral infection",
"      </strong>",
"      &minus; Cutaneous viral infections (orf and milker's nodule viruses, herpes simplex, varicella-zoster, molluscum contagiosum) may show on histologic examination large atypical CD30+ cells [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/58,64\">",
"       58,64",
"      </a>",
"      ]. In contrast to LyP, skin lesions caused by viruses do not have a waxing and waning clinical course and do not show",
"      <em>",
"       T-cell-receptor",
"      </em>",
"      (",
"      <em>",
"       TCR)",
"      </em>",
"      gene rearrangement on molecular genetic studies. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Other",
"      </strong>",
"      &minus; CD30+ T cells may also be found in skin lesions of atopic dermatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/65-68\">",
"       65-68",
"      </a>",
"      ], mycobacterial infection [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/69\">",
"       69",
"      </a>",
"      ], syphilis, and leishmaniasis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/58\">",
"       58",
"      </a>",
"      ]. The history and clinical course are usually sufficient to differentiate these conditions from LyP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18325895\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of a patient with a diagnosis of lymphomatoid papulosis (LyP) requires coordinated care by a dermatologist and a primary care provider. Consultation with a",
"    <span class=\"nowrap\">",
"     hematologist/oncologist",
"    </span>",
"    may be needed to exclude or treat an associated malignant lymphoma.",
"   </p>",
"   <p>",
"    Before treatment for LyP, it is necessary to exclude an associated malignant lymphoma, through history, examination, and laboratory studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historical features that increase the risk of malignant lymphoma include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous lymphoid neoplasm, particularly Hodgkin lymphoma (HL), systemic anaplastic large cell lymphoma (ALCL), or mycosis fungoides (MF)",
"     </li>",
"     <li>",
"      Systemic symptoms such as unexplained weight loss, fever, night sweats, shortness of breath, abdominal fullness",
"     </li>",
"     <li>",
"      HIV infection or immunosuppressive therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examination findings that may suggest malignant lymphoma include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Morphology, size, and extent of skin lesions (isolated or few lesions that are larger than 2 cm are more suggestive of cutaneous ALCL than LyP) (",
"      <a class=\"graphic graphic_picture graphicRef83092 graphicRef83091 graphicRef83089 graphicRef83095 \" href=\"UTD.htm?40/59/41914\">",
"       picture 3A-D",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Erythematous, scaly patches and plaques (suggestive of mycosis fungoides (",
"      <a class=\"graphic graphic_picture graphicRef80073 graphicRef60650 graphicRef52131 graphicRef73078 \" href=\"UTD.htm?34/30/35306\">",
"       picture 7A-D",
"      </a>",
"      ))",
"     </li>",
"     <li>",
"      Lymph node enlargement",
"     </li>",
"     <li>",
"      Hepatic or splenic enlargement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory investigations that may be helpful in the pretreatment evaluation of patients with LyP include: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood cell count and differential",
"     </li>",
"     <li>",
"      Examination of a peripheral blood smear for the presence of atypical cells",
"     </li>",
"     <li>",
"      Routine biochemistry tests including LDH",
"     </li>",
"     <li>",
"      HTLV-1 serology in endemic areas (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5897?source=see_link&amp;anchor=H8#H8\">",
"       \"Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology\", section on 'Epidemiology and transmission'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Imaging studies, including chest radiograph, ultrasonography of abdomen and pelvis, or computed tomography scan, are considered optional examinations in patients with typical LyP, normal laboratory tests, and absence of palpable enlarged lymph nodes, hepatosplenomegaly, and systemic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a chest radiograph at presentation may be helpful to exclude a mediastinal mass from occult Hodgkin or non-Hodgkin lymphoma. A chest-radiograph also may be warranted for patients who will be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    because preexisting lung disease may be a risk factor for lung toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6481803\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;If physical examination, blood tests, or imaging studies suggest extracutaneous lymphoproliferative disease associated with LyP, the patient should be referred to a",
"    <span class=\"nowrap\">",
"     hematologist/oncologist",
"    </span>",
"    for diagnostic evaluation, staging, and treatment of possible malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1353598\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15980835\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with LyP, treatment may hasten lesion healing and reduce the severity or prevent the eruption of new crops of lesions. However, none of the available treatment modalities alters the natural history of LyP or reduces the risk of developing an associated lymphoma. Thus, the short-term benefits of treatment should be weighed against potentially harmful side effects in the individual patient [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/57,70\">",
"     57,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have few asymptomatic lesions without scarring or other cosmetic concerns (eg, lesions not on the face or hands), a wait-and-see strategy may be appropriate, depending on patient preference.",
"     </li>",
"     <li>",
"      For patients with extensive disease or lesions involving cosmetically sensitive areas (eg, face or hands), treatment is usually required. Low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) and psoralen-UVA (PUVA) therapy are the most widely used treatments for LyP [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/57\">",
"       57",
"      </a>",
"      ]. We usually suggest MTX as initial therapy if there are no contraindications.",
"     </li>",
"     <li>",
"      Aggressive treatment with multiagent chemotherapy is unnecessary. In patients with associated lymphomas, treatment of lymphoma with multiagent chemotherapy does not alter the clinical course of LyP [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/71,72\">",
"       71,72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Skin lesions &gt;2 cm that do not regress spontaneously in eight weeks should be excised and sent for pathology [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6481914\">",
"    <span class=\"h2\">",
"     Treatment in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on treatment of LyP in children. In case series, no treatment or treatment with topical corticosteroids, oral antibiotics (macrolides or tetracyclines), UVB, or natural sunlight have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/38,73-75\">",
"     38,73-75",
"    </a>",
"    ]. Low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and bath PUVA are additional therapeutic options [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/76-78\">",
"     76-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When children require treatment because of cosmetic concerns or peer group pressure, we suggest oral macrolide or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    antibiotics or narrow band UVB therapy. We use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    30 to 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided in three or four doses (maximum daily dose 2g) for children &lt;8 years and tetracycline 25 to 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided in four doses (maximum daily dose 2 g) for children &ge;8 years. Oral antibiotics are given for four to eight weeks.",
"   </p>",
"   <p>",
"    We suggest low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    for cases that do not respond to antibiotics or UVB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82845652\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest low-dose MTX (5 to 25 mg per week by oral or subcutaneous administration) as the initial therapy for patients with symptomatic disease who require treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of MTX for LyP has not been evaluated in randomized trials. In a retrospective study including 45 patients with LyP treated with MTX 15 to 25 mg weekly, 20 patients (44 percent) did not develop new lesions and 19 patients (42 percent) developed only a few lesions during the treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/79\">",
"     79",
"    </a>",
"    ]. After discontinuation of therapy, 10 of 40 patients did not relapse during a follow-up period of 24 to 227 months. Patients with relapsing disease required maintenance treatment for months or years. Side effects were reported in 77 percent of patients, including hepatic fibrosis in 5 of 10 patients treated with MTX for more than three years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H610323371\">",
"    <span class=\"h3\">",
"     Dose and response",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment is usually started at 5 to 10 mg per week and increased by 2.5 mg per week or as tolerated to a maximum of 25",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      if a clinical improvement is not observed in four to eight weeks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link&amp;anchor=H9#H9\">",
"       \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Dosing of MTX'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lower doses of 2.5 to 15 mg per week are used in children with LyP, after other modalities have been unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/76\">",
"     76",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients receiving regular weekly MTX should also receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      1 mg per day orally. (See",
"      <a class=\"local\" href=\"#H1436730\">",
"       'Contraindications and adverse effects'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A complete response is indicated by the clearance of all the active lesions without the development of new lesions. A partial response is defined as the regression of at least 50 percent of the active lesions and development of fewer new lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Maintenance treatment may be required for long-term control of disease. Maintenance therapy is usually initiated after complete response; the dose is gradually decreased by 2.5 or 5 mg per week to the lowest effective dose.",
"     </li>",
"     <li>",
"      The duration of treatment and maintenance treatment is based upon clinical response, occurrence of side effects, and patient&rsquo;s preference. The time to relapse after discontinuation of MTX is variable and should be assessed in the individual patient. Once the decision is made to discontinue maintenance therapy, it can be discontinued without a taper.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1436730\">",
"    <span class=\"h3\">",
"     Contraindications and adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important contraindications to MTX therapy include liver disease, renal disease, and pregnancy or planned pregnancy (for both women and men) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Other contraindications to MTX are discussed separately. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     \"Methotrexate: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepatotoxicity, pulmonary fibrosis, and myelosuppression are serious adverse effects of MTX treatment and may infrequently occur with low-dose therapy. Minor adverse effects, including nausea, stomach upset, headache, and fatigue, occur in most patients treated with low-dose MTX. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rise in the mean corpuscular volume (MCV) is common in patients receiving long term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and usually indicates relative folate deficiency. The finding of low blood cell counts indicates bone marrow toxicity and prompts the discontinuation of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link&amp;anchor=H4#H4\">",
"     \"Major side effects of low-dose methotrexate\", section on 'Myelosuppression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To reduce the risk of side effects from MTX therapy without interfering with its efficacy, a daily dose of 1 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    is recommended for those patients taking MTX on a regular weekly basis. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8264995\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aminotransferases, albumin, and peripheral blood cell count should be obtained every four to eight weeks to detect hepatic and hematologic toxicity during long-term treatment with MTX.",
"   </p>",
"   <p>",
"    Guidelines for dose adjustment for patients with abnormal liver function tests are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=see_link\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82845666\">",
"    <span class=\"h2\">",
"     Phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest psoralen-ultraviolet A (PUVA) therapy for patients with LyP who do not respond to MTX or patients for whom MTX is contraindicated. (See",
"    <a class=\"local\" href=\"#H82845652\">",
"     'Methotrexate'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1436730\">",
"     'Contraindications and adverse effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    PUVA is administered twice weekly for six to eight weeks or until clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/70\">",
"     70",
"    </a>",
"    ]. Maintenance therapy with one treatment session per week may be needed to prevent relapses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=see_link&amp;anchor=H31513870#H31513870\">",
"     \"Psoralen plus ultraviolet A (PUVA) photochemotherapy\", section on 'Treatment protocols'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of PUVA for the treatment of LyP has not been evaluated in clinical trials. Its use is supported by its efficacy in other types of cutaneous lymphoproliferative disorders (eg, mycosis fungoides) and by a few case series [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/3,70\">",
"     3,70",
"    </a>",
"    ]. In a review of 19 patients treated with PUVA, a complete response was reported in 5 and a partial response in 13 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/57\">",
"     57",
"    </a>",
"    ]. Bath PUVA has been used for treatment of LyP in children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If available, UVA1 phototherapy (long-wave [340 to 400 nm] UVA therapy that does not require psoralens) may be an alternative to PUVA. In one study, UVA1 phototherapy induced a complete response in five of seven patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/82\">",
"     82",
"    </a>",
"    ]. Three patients relapsed between 1 and 20 months after discontinuation, but responded to a second treatment cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82845833\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous therapies, alone or in combination, have been used for LyP in small case series or in case reports, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Topical corticosteroids [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/38,83\">",
"       38,83",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Oral antibiotics [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Interferon-alpha [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/84,85\">",
"       84,85",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/86\">",
"       86",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Retinoids (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/10/31904?source=see_link\">",
"       bexarotene",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/87\">",
"       87",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Natural sunlight [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Radiotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/88\">",
"       88",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Multiagent chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/89\">",
"       89",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"       mechlorethamine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/90\">",
"       90",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anti-CD30 monoclonal antibody (SGN30) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/91\">",
"       91",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefits of these therapies have not been proven in clinical trials and there is limited evidence from observational studies to support their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18325902\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of lymphomatoid papulosis is excellent. Patients with LyP who do not develop malignancy have a normal life expectancy. However, patients with LyP are at increased risk of developing a cutaneous or nodal malignant lymphoma. (See",
"    <a class=\"local\" href=\"#H7532316\">",
"     'Associated lymphomas'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In two case series, each with approximately 120 patients, associated lymphoid malignancy was detected in 19 and 14 percent before, after (up to 19 years), or concurrently with the development of LyP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/3,40\">",
"     3,40",
"    </a>",
"    ]. The mortality from associated lymphoma was approximately 2 percent.",
"   </p>",
"   <p>",
"    A positive TCR gene rearrangement or the coexistence of different histologic types of LyP may be associated with an increased risk of developing a lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/23/7546/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7855060\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with lymphomatoid papulosis (LyP) require a long-term follow-up to monitor the disease course and response to treatment and lifelong surveillance for cutaneous or systemic lymphoma. Ideally, patients should be seen at six month intervals for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reassessment of clinical history",
"     </li>",
"     <li>",
"      Complete skin examination",
"     </li>",
"     <li>",
"      Physical examination focused on lymph node, hepatic, or splenic enlargement &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18325909\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphomatoid papulosis (LyP) is a rare, chronic recurrent, self-healing papulonodular skin eruption with histologic features of a CD30+ malignant lymphoma. The overexpression of CD30 on the large atypical T cell found in the skin lesions is the hallmark of LyP. Monoclonal rearrangement of the T cell receptor (",
"      <em>",
"       TCR",
"      </em>",
"      ) genes has been detected in 40 to 100 percent of the LyP skin lesions. (See",
"      <a class=\"local\" href=\"#H18325839\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18325853\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with LyP have an increased risk of associated lymphoid malignancy (mycosis fungoides, anaplastic large-cell lymphoma, or Hodgkin lymphoma) before, concurrent with, or after the onset of LyP. (See",
"      <a class=\"local\" href=\"#H7532316\">",
"       'Associated lymphomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LyP manifests as a recurrent, asymptomatic eruption of papules and nodules with central necrosis and crusting that spontaneously resolve in three to eight weeks, leaving hyperpigmentation or scarring (",
"      <a class=\"graphic graphic_picture graphicRef74972 graphicRef54022 graphicRef82762 graphicRef71441 graphicRef77791 \" href=\"UTD.htm?41/2/42026\">",
"       picture 2A-E",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7533382\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of LyP is based upon the clinical appearance and course of the skin lesions and the evaluation of an excisional biopsy of a full-developed skin lesion. Histologic characteristics include a wedge-shaped inflammatory infiltrate containing large atypical CD30+ cells (",
"      <a class=\"graphic graphic_picture graphicRef82763 graphicRef82764 \" href=\"UTD.htm?21/35/22074\">",
"       picture 1A-B",
"      </a>",
"      ). Clonal rearrangement of the",
"      <em>",
"       TCR",
"      </em>",
"      genes is found in 40 to 100 percent of cases. (See",
"      <a class=\"local\" href=\"#H18325874\">",
"       'Pathology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7711520\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of LyP includes lymphoproliferative and inflammatory or reactive disorders that contain CD30+ cells and mimic lymphomatoid papulosis clinically and histologically (",
"      <a class=\"graphic graphic_table graphicRef75494 \" href=\"UTD.htm?26/40/27276\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18325888\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Before initiating treatment, patients with LyP should be evaluated to exclude associated lymphoma. (See",
"      <a class=\"local\" href=\"#H18325895\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a wait-and-see strategy rather than medical treatment for patients who have few asymptomatic lesions without scarring or other cosmetic concerns (eg, lesions not on the face or hands) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15980835\">",
"       'General considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adults with symptomatic lesions, scarring, or cosmetic concerns, we suggest low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      rather than PUVA as the initial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The treatment is usually started at 5 to 10 mg per week orally or subcutaneously and increased by 2.5 mg per week or as tolerated to a maximum of 25",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      if clinical improvement is not observed. (See",
"      <a class=\"local\" href=\"#H82845652\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We suggest psoralen-ultraviolet A (PUVA) therapy for patients with LyP who do not respond to MTX or patients for whom MTX is contraindicated (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). PUVA is administered twice weekly for six to eight weeks or until clearance. (See",
"      <a class=\"local\" href=\"#H82845666\">",
"       'Phototherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with symptomatic lesions, scarring, or cosmetic concerns, we suggest macrolide or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      antibiotics or narrow band UVB therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      30 to 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided in three or four doses (maximum daily dose 2 g) for children &lt;8 years and tetracycline 25 to 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided in four doses (maximum daily dose 2 g) for children &ge;8 years.",
"      <br/>",
"      <br/>",
"      We suggest low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      for cases that do not respond to antibiotics or UVB (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6481914\">",
"       'Treatment in children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis of LyP is excellent. However, because of the increased life-long risk of developing a malignant lymphoma, LyP patients require long-term follow-up. (See",
"      <a class=\"local\" href=\"#H18325902\">",
"       'Prognosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7855060\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/1\">",
"      Macaulay WL. Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign--histologically malignant. Arch Dermatol 1968; 97:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/2\">",
"      Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/3\">",
"      Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95:3653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/4\">",
"      Assaf C, Gellrich S, Steinhoff M, et al. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). J Dtsch Dermatol Ges 2007; 5:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/5\">",
"      Kunishige JH, McDonald H, Alvarez G, et al. Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients. Clin Exp Dermatol 2009; 34:576.",
"     </a>",
"    </li>",
"    <li>",
"     Gomez ML. First World Congress on Cutaneous Lymphomas, Chicago, IL Sept 23-26, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/7\">",
"      Wang HH, Myers T, Lach LJ, et al. Increased risk of lymphoid and nonlymphoid malignancies in patients with lymphomatoid papulosis. Cancer 1999; 86:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/8\">",
"      Kadin ME, Vonderheid EC, Weiss LM. Absence of Epstein-Barr viral RNA in lymphomatoid papulosis. J Pathol 1993; 170:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/9\">",
"      Peters K, Knoll JH, Kadin ME. Cytogenetic findings in regressing skin lesions of lymphomatoid papulosis. Cancer Genet Cytogenet 1995; 80:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/10\">",
"      Kempf W, Kadin ME, Kutzner H, et al. Lymphomatoid papulosis and human herpesviruses--A PCR-based evaluation for the presence of human herpesvirus 6, 7 and 8 related herpesviruses. J Cutan Pathol 2001; 28:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/11\">",
"      Kempf W, Kadin ME, Dvorak AM, et al. Endogenous retroviral elements, but not exogenous retroviruses, are detected in CD30-positive lymphoproliferative disorders of the skin. Carcinogenesis 2003; 24:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/12\">",
"      Ponti R, Bergallo M, Costa C, et al. Human herpesvirus 7 detection by quantitative real time polymerase chain reaction in primary cutaneous T-cell lymphomas and healthy subjects: lack of a pathogenic role. Br J Dermatol 2008; 159:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/13\">",
"      Duvic M. CD30+ neoplasms of the skin. Curr Hematol Malig Rep 2011; 6:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/14\">",
"      Franchina M, Kadin ME, Abraham LJ. Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders. Cancer Epidemiol Biomarkers Prev 2005; 14:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/15\">",
"      Steinhoff M, Hummel M, Anagnostopoulos I, et al. Single-cell analysis of CD30+ cells in lymphomatoid papulosis demonstrates a common clonal T-cell origin. Blood 2002; 100:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/16\">",
"      Humme D, Lukowsky A, Steinhoff M, et al. Dominance of nonmalignant T-cell clones and distortion of the TCR repertoire in the peripheral blood of patients with cutaneous CD30+ lymphoproliferative disorders. J Invest Dermatol 2009; 129:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/17\">",
"      Weiss LM, Wood GS, Trela M, et al. Clonal T-cell populations in lymphomatoid papulosis. Evidence of a lymphoproliferative origin for a clinically benign disease. N Engl J Med 1986; 315:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/18\">",
"      Schultz JC, Granados S, Vonderheid EC, Hwang ST. T-cell clonality of peripheral blood lymphocytes in patients with lymphomatoid papulosis. J Am Acad Dermatol 2005; 53:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/19\">",
"      Davis TH, Morton CC, Miller-Cassman R, et al. Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N Engl J Med 1992; 326:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/20\">",
"      Chott A, Vonderheid EC, Olbricht S, et al. The dominant T cell clone is present in multiple regressing skin lesions and associated T cell lymphomas of patients with lymphomatoid papulosis. J Invest Dermatol 1996; 106:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/21\">",
"      Amagai M, Kawakubo Y, Tsuyuki A, Harada R. Lymphomatoid papulosis followed by Ki-1 positive anaplastic large cell lymphoma: proliferation of a common T-cell clone. J Dermatol 1995; 22:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/22\">",
"      Assaf C, Hummel M, Dippel E, et al. Common clonal T-cell origin in a patient with T-prolymphocytic leukaemia and associated cutaneous T-cell lymphomas. Br J Haematol 2003; 120:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/23\">",
"      Zackheim HS, Jones C, Leboit PE, et al. Lymphomatoid papulosis associated with mycosis fungoides: a study of 21 patients including analyses for clonality. J Am Acad Dermatol 2003; 49:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/24\">",
"      Basarab T, Fraser-Andrews EA, Orchard G, et al. Lymphomatoid papulosis in association with mycosis fungoides: a study of 15 cases. Br J Dermatol 1998; 139:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/25\">",
"      Volkenandt M, Bertino JR, Shenoy BV, et al. Molecular evidence for a clonal relationship between lymphomatoid papulosis and Ki-1 positive large cell anaplastic lymphoma. J Dermatol Sci 1993; 6:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/26\">",
"      Wood GS, Crooks CF, Uluer AZ. Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin. J Invest Dermatol 1995; 105:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/27\">",
"      Gallardo F, Costa C, Bellosillo B, et al. Lymphomatoid papulosis associated with mycosis fungoides: clinicopathological and molecular studies of 12 cases. Acta Derm Venereol 2004; 84:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/28\">",
"      Kadin ME, Cavaille-Coll MW, Gertz R, et al. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci U S A 1994; 91:6002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/29\">",
"      Schiemann WP, Pfeifer WM, Levi E, et al. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood 1999; 94:2854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/30\">",
"      Willemze R, Meyer CJ, Van Vloten WA, Scheffer E. The clinical and histological spectrum of lymphomatoid papulosis. Br J Dermatol 1982; 107:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/31\">",
"      DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996; 87:3437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/32\">",
"      Mathas S, Kreher S, Meaburn KJ, et al. Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma. Proc Natl Acad Sci U S A 2009; 106:5831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/33\">",
"      Braun FK, Hirsch B, Al-Yacoub N, et al. Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP. J Invest Dermatol 2010; 130:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/34\">",
"      Kikuchi A, Nishikawa T. Apoptotic and proliferating cells in cutaneous lymphoproliferative diseases. Arch Dermatol 1997; 133:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/35\">",
"      Greisser J, Doebbeling U, Roos M, et al. Apoptosis in CD30-positive lymphoproliferative disorders of the skin. Exp Dermatol 2005; 14:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/36\">",
"      Paulli M, Berti E, Boveri E, et al. Cutaneous CD30+ lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily. Hum Pathol 1998; 29:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/37\">",
"      Nevala H, Karenko L, Vakeva L, Ranki A. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis. Br J Dermatol 2001; 145:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/38\">",
"      Nijsten T, Curiel-Lewandrowski C, Kadin ME. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. Arch Dermatol 2004; 140:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/39\">",
"      Knaus PI, Lindemann D, DeCoteau JF, et al. A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol Cell Biol 1996; 16:3480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/40\">",
"      de Souza A, el-Azhary RA, Camilleri MJ, et al. In search of prognostic indicators for lymphomatoid papulosis: a retrospective study of 123 patients. J Am Acad Dermatol 2012; 66:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/41\">",
"      Kempf W, Levi E, Kamarashev J, et al. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. J Cutan Pathol 2002; 29:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/42\">",
"      Kadin ME, Pavlov IY, Delgado JC, Vonderheid EC. High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides. J Invest Dermatol 2012; 132:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/43\">",
"      Saggini A, Gulia A, Argenyi Z, et al. A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases. Am J Surg Pathol 2010; 34:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/44\">",
"      Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999; 155:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/45\">",
"      Kadin M, Nasu K, Sako D, et al. Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin's disease-associated antigens. Am J Pathol 1985; 119:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/46\">",
"      Kummer JA, Vermeer MH, Dukers D, et al. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol 1997; 109:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/47\">",
"      Kempf W. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol 2006; 33 Suppl 1:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/48\">",
"      Chimenti S, Fargnoli MC, Pacifico A, Peris K. Mucosal involvement in a patient with lymphomatoid papulosis. J Am Acad Dermatol 2001; 44:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/49\">",
"      Kato N, Tomita Y, Yoshida K, Hisai H. Involvement of the tongue by lymphomatoid papulosis. Am J Dermatopathol 1998; 20:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/50\">",
"      Heald P, Subtil A, Breneman D, Wilson LD. Persistent agmination of lymphomatoid papulosis: an equivalent of limited plaque mycosis fungoides type of cutaneous T-cell lymphoma. J Am Acad Dermatol 2007; 57:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/51\">",
"      Torrelo A, Colmenero I, Hern&aacute;ndez A, Goiriz R. Persistent agmination of lymphomatoid papulosis. Pediatr Dermatol 2009; 26:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/52\">",
"      Hsu YJ, Su LH, Hsu YL, et al. Localized lymphomatoid papulosis. J Am Acad Dermatol 2010; 62:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/53\">",
"      Chaudhari PR, Emanuel P, Levitt J. Type B follicular lymphomatoid papulosis. Cutis 2010; 85:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/54\">",
"      Kato N, Matsue K. Follicular lymphomatoid papulosis. Am J Dermatopathol 1997; 19:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/55\">",
"      Deroo-Berger MC, Skowron F, Ronger S, et al. Lymphomatoid papulosis: a localized form with acral pustular involvement. Dermatology 2002; 205:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/56\">",
"      Barnadas MA, L&oacute;pez D, Pujol RM, et al. Pustular lymphomatoid papulosis in childhood. J Am Acad Dermatol 1992; 27:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/57\">",
"      Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118:4024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/58\">",
"      Werner B, Massone C, Kerl H, Cerroni L. Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin. J Cutan Pathol 2008; 35:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/59\">",
"      Kempf W, Kazakov DV, Palmedo G, et al. Pityriasis lichenoides et varioliformis acuta with numerous CD30(+) cells: a variant mimicking lymphomatoid papulosis and other cutaneous lymphomas. A clinicopathologic, immunohistochemical, and molecular biological study of 13 cases. Am J Surg Pathol 2012; 36:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/60\">",
"      Jung J, Levin EC, Jarrett R, et al. Lymphomatoid drug reaction to ustekinumab. Arch Dermatol 2011; 147:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/61\">",
"      Saeed SA, Bazza M, Zaman M, Ryatt KS. Cefuroxime induced lymphomatoid hypersensitivity reaction. Postgrad Med J 2000; 76:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/62\">",
"      Fukamachi S, Sugita K, Sawada Y, et al. Drug-induced CD30+ T cell pseudolymphoma. Eur J Dermatol 2009; 19:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/63\">",
"      Nathan DL, Belsito DV. Carbamazepine-induced pseudolymphoma with CD-30 positive cells. J Am Acad Dermatol 1998; 38:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/64\">",
"      Leinweber B, Kerl H, Cerroni L. Histopathologic features of cutaneous herpes virus infections (herpes simplex, herpes varicella/zoster): a broad spectrum of presentations with common pseudolymphomatous aspects. Am J Surg Pathol 2006; 30:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/65\">",
"      Oflazoglu E, Simpson EL, Takiguchi R, et al. CD30 expression on CD1a+ and CD8+ cells in atopic dermatitis and correlation with disease severity. Eur J Dermatol 2008; 18:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/66\">",
"      Lipozenci J, Bobek D, Jaki-Razumovi J. The presence of surface CD30 on T cells in atopic dermatitis. Acta Dermatovenerol Croat 2003; 11:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/67\">",
"      Cavagni G, Caffarelli C, Facchetti F, et al. Cutaneous CD30+ cells in children with atopic dermatitis. Int Arch Allergy Immunol 2000; 121:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/68\">",
"      Dummer W, Rose C, Br&ouml;cker EB. Expression of CD30 on T helper cells in the inflammatory infiltrate of acute atopic dermatitis but not of allergic contact dermatitis. Arch Dermatol Res 1998; 290:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/69\">",
"      Massi D, Trotta M, Franchi A, et al. Atypical CD30+ cutaneous lymphoid proliferation in a patient with tuberculosis infection. Am J Dermatopathol 2004; 26:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/70\">",
"      Kadin ME. Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders. Oncology (Williston Park) 2009; 23:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/71\">",
"      Sanchez NP, Pittelkow MR, Muller SA, et al. The clinicopathologic spectrum of lymphomatoid papulosis: study of 31 cases. J Am Acad Dermatol 1983; 8:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/72\">",
"      Perna AG, Jones DM, Duvic M. Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel. Clin Lymphoma 2004; 5:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/73\">",
"      Van Neer FJ, Toonstra J, Van Voorst Vader PC, et al. Lymphomatoid papulosis in children: a study of 10 children registered by the Dutch Cutaneous Lymphoma Working Group. Br J Dermatol 2001; 144:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/74\">",
"      Martorell-Calatayud A, Hern&aacute;ndez-Mart&iacute;n A, Colmenero I, et al. [Lymphomatoid papulosis in children: report of 9 cases and review of the literature]. Actas Dermosifiliogr 2010; 101:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/75\">",
"      de Souza A, Camilleri MJ, Wada DA, et al. Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients. J Am Acad Dermatol 2009; 61:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/76\">",
"      Yip L, Darling S, Orchard D. Lymphomatoid papulosis in children: experience of five cases and the treatment efficacy of methotrexate. Australas J Dermatol 2011; 52:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/77\">",
"      Volkenandt M, Kerscher M, Sander C, et al. PUVA-bath photochemotherapy resulting in rapid clearance of lymphomatoid papulosis in a child. Arch Dermatol 1995; 131:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/78\">",
"      Hoetzenecker W, Guenova E, Hoetzenecker K, et al. Successful treatment of recalcitrant lymphomatoid papulosis in a child with PUVA-bath photochemotherapy. Eur J Dermatol 2009; 19:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/79\">",
"      Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996; 34:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/80\">",
"      Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther 2007; 20:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/81\">",
"      Shen S, O'Brien T, Yap LM, et al. The use of methotrexate in dermatology: a review. Australas J Dermatol 2012; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/82\">",
"      Calzavara-Pinton P, Venturini M, Sala R. Medium-dose UVA1 therapy of lymphomatoid papulosis. J Am Acad Dermatol 2005; 52:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/83\">",
"      Paul MA, Krowchuk DP, Hitchcock MG, Jorizzo JL. Lymphomatoid papulosis: successful weekly pulse superpotent topical corticosteroid therapy in three pediatric patients. Pediatr Dermatol 1996; 13:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/84\">",
"      Schmuth M, Topar G, Illersperger B, et al. Therapeutic use of interferon-alpha for lymphomatoid papulosis. Cancer 2000; 89:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/85\">",
"      Wyss M, Dummer R, Dommann SN, et al. Lymphomatoid papulosis--treatment with recombinant interferon alfa-2a and etretinate. Dermatology 1995; 190:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/86\">",
"      Hughes PS. Treatment of lymphomatoid papulosis with imiquimod 5% cream. J Am Acad Dermatol 2006; 54:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/87\">",
"      Krathen RA, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology 2003; 206:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/88\">",
"      Kaufmann T, Nisce LZ, Silver RT. Lymphomatoid papulosis: case report of a patient managed with radiation therapy and review of the literature. Am J Clin Oncol 1992; 15:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/89\">",
"      Zackheim HS, LeBoit PE, Gordon BI, Glassberg AB. Lymphomatoid papulosis followed by Hodgkin's lymphoma. Differential response to therapy. Arch Dermatol 1993; 129:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/90\">",
"      Zackheim HS, Epstein EH Jr, Crain WR. Topical carmustine therapy for lymphomatoid papulosis. Arch Dermatol 1985; 121:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/23/7546/abstract/91\">",
"      Duvic M, Reddy SA, Pinter-Brown L, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 2009; 15:6217.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15725 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_23_7546=[""].join("\n");
var outline_f7_23_7546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18325909\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18325839\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18325846\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18325853\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7532316\">",
"      ASSOCIATED LYMPHOMAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18325874\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8448414\">",
"      Histologic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18325881\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H610323182\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533382\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7711520\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20514972\">",
"      Diagnostic pitfalls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18325888\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8448437\">",
"      CD30+ lymphoproliferative diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8448445\">",
"      CD30+ inflammatory and infectious diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18325895\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6481803\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1353598\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15980835\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6481914\">",
"      Treatment in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H82845652\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H610323371\">",
"      - Dose and response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1436730\">",
"      - Contraindications and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8264995\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H82845666\">",
"      Phototherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H82845833\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18325902\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7855060\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18325909\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15725\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15725|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/13/37080\" title=\"picture 1A\">",
"      Lymphomatoid papulosis histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/41/31379\" title=\"picture 1B\">",
"      Lymphomatoid papulosis histo 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/20/12611\" title=\"picture 2A\">",
"      Lymphomatoid papulosis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/24/1412\" title=\"picture 2B\">",
"      Lymphomatoid papulosis 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/46/41697\" title=\"picture 2C\">",
"      Lymphomatoid papulosis arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/1/13333\" title=\"picture 2D\">",
"      Lymphomatoid papulosis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/60/42946\" title=\"picture 2E\">",
"      Lymphomatoid papulosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/47/2804\" title=\"picture 3A\">",
"      Anaplastic large cell lymphoma skin 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/18/7460\" title=\"picture 3B\">",
"      Anaplastic large cell lymphoma skin 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/27/11704\" title=\"picture 3C\">",
"      Anaplastic large cell lymphoma skin 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/33/24082\" title=\"picture 3D\">",
"      Hodgkin lymphoma skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/29/9685\" title=\"picture 4A\">",
"      Pityriasis lichenoides et varioliformis acuta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/60/40897\" title=\"picture 4B\">",
"      PLEVA 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/38/23138\" title=\"picture 5A\">",
"      Scabies axilla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/30/9697\" title=\"picture 5B\">",
"      Scabies buttocks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/57/39829\" title=\"picture 5C\">",
"      Scabies nodular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/26/38306\" title=\"picture 6\">",
"      Drug eruption lymphomatoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/16/34052\" title=\"picture 7A\">",
"      Mycosis fungoides patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/36/35393\" title=\"picture 7B\">",
"      Mycosis fungoides patches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/17/38163\" title=\"picture 7C\">",
"      Mycosis fungoides plaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/2/35873\" title=\"picture 7D\">",
"      Mycosis fungoides plaque",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15725|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/40/27276\" title=\"table 1\">",
"      Lymphomatoid papulosis differential",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35126?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T-cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=related_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5897?source=related_link\">",
"      Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=related_link\">",
"      Methotrexate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17369?source=related_link\">",
"      Pityriasis lichenoides et varioliformis acuta (PLEVA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=related_link\">",
"      Psoralen plus ultraviolet A (PUVA) photochemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=related_link\">",
"      Scabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4713?source=related_link\">",
"      Staging and prognosis of mycosis fungoides and S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_23_7547="ILD associated BAL neutrophilia";
var content_f7_23_7547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Interstitial lung disease associated with BAL neutrophilia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Idiopathic pulmonary fibrosis (15 to 40 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptogenic organizing pneumonia (40 to 70 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Inorganic dust diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Asbestosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Silicosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cigarette smoking (&lt;10 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary Langerhans cell histiocytosis (Histiocytosis X)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersensitivity pneumonitis (acute)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis (advanced)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BAL: bronchoalveolar lavage.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_23_7547=[""].join("\n");
var outline_f7_23_7547=null;
var title_f7_23_7548="Effects of antihypertensive treatment in the elderly";
var content_f7_23_7548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F83927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F83927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Effects of antihypertensive treatment in the elderly",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        HYVET",
"       </td>",
"       <td class=\"subtitle1\">",
"        SHEP",
"       </td>",
"       <td class=\"subtitle1\">",
"        STOP",
"       </td>",
"       <td class=\"subtitle1\">",
"        Syst-Eur",
"       </td>",
"       <td class=\"subtitle1\">",
"        Syst-China",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mean treatment BP reduction, SBP/DBP, mmHg",
"       </td>",
"       <td>",
"        -29/-13",
"       </td>",
"       <td>",
"        -27/-9",
"       </td>",
"       <td>",
"        -29/-17",
"       </td>",
"       <td>",
"        -23/-7",
"       </td>",
"       <td>",
"        -20/-5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stroke,",
"        <br/>",
"        percent reduction",
"       </td>",
"       <td>",
"        -30 percent",
"       </td>",
"       <td>",
"        -32 percent",
"       </td>",
"       <td>",
"        -47 percent",
"       </td>",
"       <td>",
"        -42 percent",
"       </td>",
"       <td>",
"        -38 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary disease,",
"        <br/>",
"        percent reduction",
"       </td>",
"       <td>",
"        -23 percent*",
"       </td>",
"       <td>",
"        -27 percent",
"       </td>",
"       <td>",
"        -13 percent",
"       </td>",
"       <td>",
"        -30 percent",
"       </td>",
"       <td>",
"        +6 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart failure,",
"        <br/>",
"        percent reduction",
"       </td>",
"       <td>",
"        -64 percent",
"       </td>",
"       <td>",
"        -55 percent",
"       </td>",
"       <td>",
"        -51 percent",
"       </td>",
"       <td>",
"        -29 percent",
"       </td>",
"       <td>",
"        -58 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SHEP: Systolic Hypertension in the Elderly Program; STOP: Swedish Trial in Old Patients; HYVET: Hypertension in Very Elderly Trial; Sys-Eur: European Systolic Hypertension in the Elderly; Syst-China: Chinese Trial on Isolated Systolic Hypertension in Elderly.",
"     <br/>",
"     * Percentage of cardiovascular mortality reduction.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Burney B, Bakris G. Hypertension and its management in the elderly. Semin Nephrol 2009; 29:604. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_23_7548=[""].join("\n");
var outline_f7_23_7548=null;
var title_f7_23_7549="Emetogenicity chemo drugs";
var content_f7_23_7549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Emetogenicity of parenteral chemotherapeutic drugs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"25%\">",
"     </colgroup>",
"     <colgroup width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Level",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency of emesis, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chemotherapeutic drug and dose",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        &gt;90",
"       </td>",
"       <td>",
"        <p>",
"         Carmustine",
"        </p>",
"        <p>",
"         Cisplatin",
"        </p>",
"        <p>",
"         Cyclophosphamide &ge;1500 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"        <p>",
"         Dacarbazine",
"        </p>",
"        <p>",
"         Dactinomycin",
"        </p>",
"        <p>",
"         Mechlorethamine",
"        </p>",
"        <p>",
"         Streptozotocin",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        30-90",
"       </td>",
"       <td>",
"        <p>",
"         Alemtuzumab",
"        </p>",
"        <p>",
"         Azacytidine",
"        </p>",
"        <p>",
"         Bendamustine",
"        </p>",
"        <p>",
"         Cabazitaxel",
"        </p>",
"        <p>",
"         Carboplatin",
"        </p>",
"        <p>",
"         Clofaribine",
"        </p>",
"        <p>",
"         Cyclophosphamide &lt;1500 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"        <p>",
"         Cytarabine &gt;1000 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"        <p>",
"         Daunorubicin*",
"        </p>",
"        <p>",
"         Denileukin diftitox",
"        </p>",
"        <p>",
"         Doxorubicin*",
"        </p>",
"        <p>",
"         Epirubicin*",
"        </p>",
"        <p>",
"         Idarubicin*",
"        </p>",
"        <p>",
"         Ifosfamide",
"        </p>",
"        <p>",
"         Irinotecan",
"        </p>",
"        <p>",
"         Oxaliplatin",
"        </p>",
"        <p>",
"         Pralatrexate",
"        </p>",
"        <p>",
"         Temozolomide",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        10-30",
"       </td>",
"       <td>",
"        <p>",
"         Bortezomib",
"        </p>",
"        <p>",
"         Carfilzomib",
"        </p>",
"        <p>",
"         Cytarabine &le;1000 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"        <p>",
"         Docetaxel",
"        </p>",
"        <p>",
"         Eribulin",
"        </p>",
"        <p>",
"         Etoposide",
"        </p>",
"        <p>",
"         Fluorouracil",
"        </p>",
"        <p>",
"         Gemcitabine",
"        </p>",
"        <p>",
"         Ixabepilone",
"        </p>",
"        <p>",
"         Methotrexate",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Mitomycin",
"        </p>",
"        <p>",
"         Mitoxantrone",
"        </p>",
"        <p>",
"         Paclitaxel",
"        </p>",
"        <p>",
"         Panitumumab",
"        </p>",
"        <p>",
"         Pegylated liposomal doxorubicin",
"        </p>",
"        <p>",
"         Pemetrexed",
"        </p>",
"        <p>",
"         Romidepsin",
"        </p>",
"        <p>",
"         Temsirolimus",
"        </p>",
"        <p>",
"         Topotecan",
"        </p>",
"        <p>",
"         Trastuzumab",
"        </p>",
"        <p>",
"         Trastuzumab emtansine",
"        </p>",
"        <p>",
"         Vorinostat",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimal",
"       </td>",
"       <td>",
"        &lt;10",
"       </td>",
"       <td>",
"        <p>",
"         2-Chlorodeoxyadenosine",
"        </p>",
"        <p>",
"         Bevacizumab",
"        </p>",
"        <p>",
"         Bleomycin",
"        </p>",
"        <p>",
"         Busulfan",
"        </p>",
"        <p>",
"         Cetuximab",
"        </p>",
"        <p>",
"         Fludarabine",
"        </p>",
"        <p>",
"         Rituximab",
"        </p>",
"        <p>",
"         Vinblastine",
"        </p>",
"        <p>",
"         Vincristine",
"        </p>",
"        <p>",
"         Vinorelbine",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These anthracyclines, when combined with cyclophosphamide, are now designated as having high emetic risk.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     At doses &gt;1 gram, methotrexate has at least moderate emetogenic potential.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with updated data from: Basch E, Prestrud A, and Hesketh P, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2011; 29:4189.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_23_7549=[""].join("\n");
var outline_f7_23_7549=null;
var title_f7_23_7550="Distal muscular dystrophies";
var content_f7_23_7550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distal muscular dystrophies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inheritance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean age of onset",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial weakness",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum creatine kinase",
"       </td>",
"       <td class=\"subtitle1\">",
"        Biopsy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Locus/gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonaka distal myopathy (hereditary inclusion body myopathy*)",
"       </td>",
"       <td>",
"        Autosomal recessive or sporadic",
"       </td>",
"       <td>",
"        15 to 20",
"       </td>",
"       <td>",
"        Legs: anterior compartment",
"       </td>",
"       <td>",
"        Slightly to moderately increased, usually &lt;10 times normal",
"       </td>",
"       <td>",
"        Myopathic with rimmed vacuoles",
"       </td>",
"       <td>",
"        <p>",
"         9p13.3",
"        </p>",
"        <p>",
"         GNE",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miyoshi muscular dystrophy 1 (LGMD 2B&bull;)",
"       </td>",
"       <td>",
"        Autosomal recessive or sporadic",
"       </td>",
"       <td>",
"        &lt;20",
"       </td>",
"       <td>",
"        Legs: posterior compartment",
"       </td>",
"       <td>",
"        Increased 10 to 100 times normal",
"       </td>",
"       <td>",
"        Myopathic, usually without vacuoles; gastrocnemius often 'end stage'",
"       </td>",
"       <td>",
"        <p>",
"         2p13.3",
"        </p>",
"        <p>",
"         DYSF",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miyoshi muscular dystrophy 3 (LGMD2L&loz;)",
"       </td>",
"       <td>",
"        Autosomal recessive",
"       </td>",
"       <td>",
"        &nbsp;&gt;20",
"       </td>",
"       <td>",
"        Legs: posterior compartment",
"       </td>",
"       <td>",
"        Increased 20 to 50 times normal",
"       </td>",
"       <td>",
"        Myopathic",
"       </td>",
"       <td>",
"        11p14.3",
"        <br/>",
"        ANO5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Welander distal myopathy",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"       <td>",
"        &gt;40",
"       </td>",
"       <td>",
"        Hands: fingers and wrist extensors",
"       </td>",
"       <td>",
"        Normal or slightly increased",
"       </td>",
"       <td>",
"        Myopathic; rimmed vacuoles in some cases",
"       </td>",
"       <td>",
"        2p13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Udd distal myopathy",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"       <td>",
"        &gt;35",
"       </td>",
"       <td>",
"        Legs: anterior compartment",
"       </td>",
"       <td>",
"        Normal or slightly increased",
"       </td>",
"       <td>",
"        Vacuolar myopathy",
"       </td>",
"       <td>",
"        <p>",
"         2q31",
"        </p>",
"        <p>",
"         TTN",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Markesbery-Griggs late onset distal myopathy",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"       <td>",
"        &gt;40",
"       </td>",
"       <td>",
"        Legs: anterior compartment",
"       </td>",
"       <td>",
"        Normal or slightly increased",
"       </td>",
"       <td>",
"        Vacuolar and myofibrillar myopathy",
"       </td>",
"       <td>",
"        <p>",
"         10q22.3-q23.2",
"        </p>",
"        <p>",
"         LDB3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal myotilinopathy",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"       <td>",
"        &gt;40",
"       </td>",
"       <td>",
"        Legs: posterior &gt; anterior compartment",
"       </td>",
"       <td>",
"        Slightly increased",
"       </td>",
"       <td>",
"        Vacuolar and myofibrillar myopathy",
"       </td>",
"       <td>",
"        <p>",
"         5q31",
"        </p>",
"        <p>",
"         MYOT",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laing distal myopathy (MPD1)",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"       <td>",
"        &lt;20",
"       </td>",
"       <td>",
"        Legs: anterior compartment; neck flexors",
"       </td>",
"       <td>",
"        Slightly increased to &le;3 times normal",
"       </td>",
"       <td>",
"        Moderate myopathic changes; no vacuoles",
"       </td>",
"       <td>",
"        <p>",
"         14q12",
"        </p>",
"        <p>",
"         MYH7",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal myopathy with vocal cord and pharyngeal signs (MPD2)",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"       <td>",
"        35 to 60",
"       </td>",
"       <td>",
"        Asymmetric lower legs and hands; dysphonia",
"       </td>",
"       <td>",
"        1 to 8 times normal",
"       </td>",
"       <td>",
"        Rimmed vacuoles",
"       </td>",
"       <td>",
"        <p>",
"         5q31",
"        </p>",
"        <p>",
"         MATR3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New Finnish distal myopathy (MPD3)",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"       <td>",
"        &gt;30",
"       </td>",
"       <td>",
"        Hands or anterior lower legs",
"       </td>",
"       <td>",
"        1 to 4 times normal",
"       </td>",
"       <td>",
"        Dystrophic; rimmed vacuoles, eosinophilic inclusions",
"       </td>",
"       <td>",
"        8p22-q11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Williams distal myopathy (MPD4)",
"       </td>",
"       <td>",
"        Autosomal dominant&nbsp;",
"       </td>",
"       <td>",
"        20 to 40",
"       </td>",
"       <td>",
"        Hands",
"       </td>",
"       <td>",
"        Normal to 6 times normal",
"       </td>",
"       <td>",
"        Normal, or myopathic changes",
"       </td>",
"       <td>",
"        <p>",
"         7q32.1",
"        </p>",
"        <p>",
"         FLNC",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal myopathy with pes cavus and areflexia (vacuolar neuromyopathy)",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"       <td>",
"        15 to 50",
"       </td>",
"       <td>",
"        Legs: lower anterior and posterior; dysphonia and dysphagia",
"       </td>",
"       <td>",
"        2 to 6 times normal",
"       </td>",
"       <td>",
"        Dystrophic, rimmed vacuoles",
"       </td>",
"       <td>",
"        19p13.3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ANO5: Anoctamin 5 gene; DYSF: dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive) gene; FLNC: Filamin C, gamma gene; GNE: UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene; LDB3: LIM domain binding 3 gene; MATR3: matrin 3 gene; MPD1: distal myopathy 1; MPD2: distal myopathy 2; MPD3: distal myopathy 3; MPD4: distal myopathy 4; MYH7: myosin heavy chain 7 cardiac muscle beta gene; MYOT: myotilin gene; TTN: titin gene.",
"     <br>",
"      * Autosomal recessive hereditary inclusion body myopathy (HIBM or IBM2), also known as quadriceps sparing myopathy, and Nonaka distal myopathy are allelic disorders caused by mutations in the GNE gene.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Limb girdle muscular dystrophy type 2B co-localizes with Miyoshi muscular dystrophy 1.",
"       <br>",
"        &loz; Limb girdle muscular dystrophy type 2L co-localizes with Miyoshi muscular dystrophy 3.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Orrell, RW, Darras, BT, Griggs, RC. Facioscapulohumeral dystrophy, scapuloperoneal syndromes, and distal myopathies. In: Neuromuscular disorders in infancy, childhood, and adolescence: A clinician's approach, Jones, HR, De Vivo, DC, Darras, BT (Eds), Butterworth Heinemann, Philadelphia 2003. p.701. Copyright &copy; 2003 Elsevier.",
"     <br>",
"      Additional data from:",
"      <br>",
"       1. Suominen, T, Udd, B, Hackman, P. Udd distal myopathy. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1323/ (Accessed on January 18, 2011)",
"       <br>",
"        2. Guergueltcheva V, Peeters K, Baets J, et al. Distal myopathy with upper limb predominance caused by filamin C haploinsufficiency. Neurology 2011; 77:2105.",
"        <br>",
"         3. Schessl J, Kress W, Schoser B. Novel ANO5 mutations causing hyper-CK-emia, limb girdle muscular weakness and Miyoshi type of muscular dystrophy. Muscle Nerve 2012; 45:740.",
"         <br>",
"          4.",
"          <a href=\"file://www.ncbi.nlm.nih.gov/omim\" style=\"FONT-STYLE: italic\">",
"           Online Mendelian Inheritance in Man",
"          </a>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_23_7550=[""].join("\n");
var outline_f7_23_7550=null;
var title_f7_23_7551="Stand on one foot";
var content_f7_23_7551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Balance exercise: Stand on one foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    You can do this exercise while waiting for the bus or standing in line at the grocery. For an added challenge, you can modify the exercise to improve your balance.",
"    <ol>",
"     <li>",
"      Stand on one foot behind a sturdy chair, holding on for balance.",
"     </li>",
"     <li>",
"      Hold position for up to 10 seconds.",
"     </li>",
"     <li>",
"      Repeat 10 to 15 times.",
"     </li>",
"     <li>",
"      Repeat 10 to 15 times with other leg.",
"     </li>",
"     <li>",
"      Repeat 10 to 15 more times with each leg.",
"     </li>",
"    </ol>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_23_7551=[""].join("\n");
var outline_f7_23_7551=null;
  